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Abstract
This research sets out to build upon excited state o-azaxylylene cycloaddition.
The mechanism behind the excitation and cycloaddition process of photogenerated oazaxylylenes was determined experimentally. Time-correlated single-photon counting,
steady-state spectroscopy, triplet quenching experiments, and quantum yield studies
provided evidence suggesting that excited state intramolecular proton transfer is followed
by intersystem crossing and stepwise addition to the tethered unsaturated pendant.
In keeping with the principles of diversity oriented synthesis, a modular approach
was taken to gain access to a diverse array of N,O,S-Polyheterocycles which were
modified postphotochemically via Suzuki coupling to yield fused biaryls. Cycloaddition
products, outfitted with halogens in the aromatic ring of the o-azaxylylene, proved to be
reactive with a variety of boronic acids resulting in a rapid growth in structural
complexity.
A novel procedure was developed that utilized multiple o-azaxylylene cores in a
photochemical cascade transformation yielding complex scaffolds of unprecedented
topology. The photoprecursors were produced in a one-pot two-step sequence from
commercially available starting materials, and upon irradiation yield structures containing
up to five fused hetrocyclic rings, and showed complete diastereoselectivity.
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Chapter One: Introduction
In 2014 $373.9 billion was spent on prescription drugs in the U.S. alone, an
increase of 13.1% ($43.4 billion) from the previous year.1 Per capita spending in 2014
almost tripled since 1995, an increase from $339 to $995 when adjusted to 2005 dollars,
and record spending on new brands was observed, totaling $20.2 billion, tripling that in
2013.1 This recent upward trend in pharmaceutical spending has been driven by an
increased emphasis on healthcare in the United States. In 2014 15.7 million people
gained health insurance coverage as a result of the Affordable Care Act, and patients
filled prescriptions 25.4% more often in states with expanded Medicaid eligibility.1
Given the growing demand for healthcare, there is a substantial amount of funding that
goes into the research and development for the industry. Approximately $30.3 billion in
funding is supplied by the National Institute of Health annually to medical research,2 and
R&D spending by the pharmaceutical industry totaled $51.1 billion in 2013.3 Given the
large investment into the pharmaceutical industry, as well as the amount of time and
effort spent producing new drugs, it’s staggering to see just how few new active
substances are introduced on an annual basis.
At the time this document was written, the CAS registry just reached a 100
million compounds,4 the majority being small molecules,5 and annually over 4 million
new compounds are submitted; however, only 42 New Active Substances were
1

introduced in 2014, the most since 2001.1 The stark contrast between the number of
compounds submitted to the CAS registry and the number of new active substances is
striking. One possible explanation is the obvious discrepancy between the structure of
new active substances and those synthesized in the laboratory. Szychowski et al.
emphasize that “despite the prevalence of combinatorially derived libraries in the
pharmaceutical industry,” from January 1981 to December 2010, over half of new active
drugs were either natural products (NP) or derivatives,6 and
when compared to compounds prepared by combinatorial approaches, NPs tend to
(a) have more stereogenic centers, (b) have a larger fraction of sp3 carbons, (c) be
less hydrophobic, (d) have more oxygen atoms, (e) have fewer nitrogens, sulfurs,
and halogens, (f) have fewer rotatable bonds, (g) have more fused, bridge, and
spiro rings, and (h) have more solvated hydrogen bond donors and acceptors.6
Combinatorial chemistry further compounds the problem, as this methodology yields
structurally similar products by design, ignoring a vast and unexplored region of
chemical space. Half of the compounds submitted to the CAS registry contain one of 143
basic frameworks,7 and this lack of structural diversity can partially be attributed to the
synthetic cost of developing new molecular architecture,7 as modifications to the core
framework pose a greater synthetic challenge than modifying the perimeter of an
established scaffold.
Given the amount of time and money, as well as the importance of healthcare, it is
disturbing to see a trend where many compounds synthesized by combinational
methodology lack structural diversity and do not conform to the trends put forth by the
body of data which support biological activity. To address this issue, new approaches
and a greater amount of structural diversity must be incorporated into scientific
2

methodology in the future. The research within this dissertation focuses on the
photochemical transformations of o-azaxylylenes which yield complex structures of
unprecedented topology containing multiple fused rings, chiral centers, a high degree of
saturation, and few rotatable bonds, all of which are characteristic of natural products.
Below (Scheme 1.1) is a representative example, from the research presented in this
dissertation, of the spectacular growth of complexity which can be generated in three
steps, from affordable starting materials, and obtained in high purity without column
chromatography. This methodology is based on diversity oriented synthesis, an approach
that probes a greater region of chemical space when compared to conventional
combinatorial methods.

Scheme 1.1

Synthetic Methodology
Chemical space is an abstract idea that places all possible molecules in a
multidimensional coordinate system according to their structure and physical properties.
Reymond et al. explains chemical space as a “geographical map to illustrate the
3

distribution of molecules and their properties,”8 notes that there are thousands of different
descriptors, and as a result many dimensions from which this map can be derived,
“including atom and bond types, polar groups, and topological features.” It is the
unexplored region of chemical space where new drug discovery takes place, and there are
three general approaches to small molecule synthesis, all of which sample a different
region of this chemical space: target oriented synthesis (TOS), combinatorial chemistry,
and diversity oriented synthesis (DOS).9
TOS is a process that aims to synthesize a specific compound, usually a natural
product, which is known to have a desired biological activity. This approach is (i) based
on a retrosynthetic methodology, (ii) only aims to synthesize one specific compound, and
as a result (iii) only probes one coordinate of chemical space. Combinatorial chemistry
differs from TOS in that it aims to decorate a known biologically active core scaffold
with various functional groups leading to a library of new compounds. This methodology
probes a greater region of chemical space than TOS, but is somewhat restricted in the
region of chemical space that it explores given the conservation of the core scaffold.
DOS is a forward-thinking methodology that aims to probe the largest region of chemical
space possible, in that multiple modifications are performed throughout the synthesis,
including that of the core scaffold, producing a large number of significantly diverse
compounds.
A famous example of target oriented synthesis is Taxol® (Figure 1.1), an
anticancer drug that was initially isolated as a natural product from the Pacific yew tree
(Taxus brevifolia).10 Harvesting the drug from natural sources was impractical, as 38,000
4

Taxus brevifolia trees would be needed to yield just 25 kg of Taxol®, and three trees
would be needed to treat one person.

Figure 1.1

It took around two decades for a total synthesis to be accomplished given the
complexity of the molecule, as it contains a complex 6:8:6 fused ring system, 11 chiral
centers, and is densely populated with various functional groups.10 One of the first total
synthetic pathways, developed by Nicolaou et al., was accomplished in 51 steps with an
overall yield of 0.4%.11 Total synthesis is important, as the process often advances
synthetic methodology, and there may be no other way to access these valuable scaffolds.
However, when searching for new biologically active drugs, it’s vital to probe the
greatest region of chemical space possible. Both combinatorial chemistry and diversity
oriented synthesis are valuable tools, as they are capable of producing large libraries of
compounds efficiently. A forward thinking DOS philosophy should be implemented in
conjunction with combinatorial chemistry to probe the greatest area of chemical space
possible in hopes to find new drug candidates.
The principal concept behind diversity oriented synthesis is to efficiently produce
a large library of compounds that are significantly different from one another so that a
5

greater region of chemical space can be explored. To do this, multiple modifications are
performed after each step in the sequence resulting in the multiplicative growth of diverse
compounds resulting from the synthesis. At each stage stereocenters, appendages, and
modifications to the core framework can be introduced. An example of DOS can be seen
in Scheme 1.2, which is centered around o-azaxylylene photochemistry and is an excerpt
from the research presented in this dissertation.12

6

Scheme 1.2
7

Peripheral decoration of a core scaffold with functional groups is common place
in combinatorial chemistry, as the core scaffold remains the same9, and there are many
examples of this in Scheme 1.2, such as the addition of benzylamine or furfuryl amine
However, the most significant transformation can be seen when the overall topology
changes in the core framework, the cornerstone of DOS, which occurs upon irradiation
yielding significantly different [4 + 4] and [4 + 2] isomers. Not only does this irradiation
produce diverse scaffolds, but it also introduces 3 stereocenters, and some of the resultant
assemblies contain fragments that are found in active pharmaceuticals, such as a fused
2,5-diketopiperazine ring. This fragment is the core template in many bioactive
molecules (Figure 1.2), such as PDE-5 inhibitors (Cialis), preterm labor drugs
(Retosiban), various cancer inhibitors (Phenylahistin), and “are among the most
numerous of all naturally occurring peptide antibiotics.”13

Figure 1.2

In keeping with the principles of DOS, further modifications to the synthetic
methodology behind o-azaxylylene photochemistry have been implemented by various

8

members of Dr. Kutateladze’s lab yielding structurally diverse scaffolds,14-16 and a small
subset can be seen in Figure 1.3.

Figure 1.3

All the above examples were synthesized by utilizing intramolecular addition to
o-azaxylylenes in the excited state, and it should be clear just by looking at Figure 1.3
that this methodology is a powerful technique capable of yielding significantly distinct
topologies in keeping with the fundamentals of DOS.

o-Azaxylylenes
o-Azaxylylenes (1.1a) have been explored for over half a century, and throughout
their history have been utilized as unstable heterodiene intermediates in a few [4 + 2]
cycloaddition reactions with only a handful of dienophiles (Scheme 1.3).17

9

Scheme 1.3

Prior to 2011, approaches to the in situ generation of o-azaxylylenes could be
broken down into six categories (Scheme 1.4); nitrene formation followed by a [1,4]hydrogen shift (1.1b), valence isomerization of strained benzoazetines (1.1c), thermal
cheleotropic extrusion of SO2 (1.1d) or CO, [4 + 2] cycloreversions (1.1e), ring-opening
of heterocyclic systems (1.1f), and elimination (1.1g).17

Scheme 1.4
10

One thing that should be noted when looking at Scheme 1.4 is that the conditions
are typically harsh, requiring high temperatures or even flash vacuum thermolysis (FVT),
and as a result are not compatible with many substrates. Before 2011 there were few
examples of dieneophiles outside of N-phenylmaleimide (NPMI), or basic alkenes and
alkynes that were reactive with the o-azaxylylene core.17 Below (Scheme 1.5) is the
synthetic sequence used by Burgess and McCullagh to trap an o-azaxylylene intermediate
with NPMI, which is also the first experimental proof of o-azaxylylene formation.18

Scheme 1.5

Though most of the methods in Scheme 1.4 are harsh, special attention should be
paid to the synthesis utilizing substrate 1.1g, which “involves base-induced elimination of
hydrogen chloride from amide or sulfonamide derivitives,”19 and was thought at the time
to be “the simplest method possible for o-azaxylylene production …” Steinhagen and
Corey demonstrated that this methodology can be used for intermolecular and
intramolecular [4 + 2] cyclization of electron rich olefins without the need for drastic
conditions, allowing access to a handful of unique structures including the core scaffold
of virantmycin, an antiviral agent, as a racemic mixture in respectable yields (Scheme
1.6).
11

Scheme 1.6

On paper this method for generating o-azaxylylenes looks simple; however, the
actual process is not without its difficulties. Synthesis involves the addition of the
cholormethylaniline derivative to the base and diene by syringe pump over, and
depending on the substrate this can take up to 24 hours while maintaining a temperature
as low as -78 °C.19

Photogenerated o-Azaxylylenes
For ten years Steinhagen and Corey’s19 methodology would stand as the only
viable way to utilize azaxylylenes synthetically, until 2011 when Mukhina et al., a fellow
group member, reported the first example of [4 + 2] and [4 + 4] cycloadditions stemming
from the excited state intramolecular proton transfer (ESIPT) of photogenerated oazaxylylenes in the formation of complex N,O,S-Polyheterocycles.20 This novel
approach is advantageous over the preceding methodology, as it eliminates the need for
harsh conditions or reagents that may not be accommodating to substrates. The
irradiation process is about as simple as flipping a switch, and allows access to [4 + 4]
cycloaddition products, a process that is forbidden in the ground state, in addition to the
[4 + 2] cyclization products. A representative from the work of Mukhina et al. is
12

depicted in Scheme 1.7. This simple synthetic sequence involves coupling 2’aminoacetophenone with the acyl chloride produced from 3-(2-furyl)propionic acid, and
subsequent irradiation of the photoprecursor (1.2) yielding the [4 + 2] (1.3), and [4 + 4]
(1.4) cycloaddition products in only three steps. Given the simplicity of this method it is
staggering that it had not been discovered earlier, and the authors note that “it is
conceivable that [photochemical generation of azaxylylenes] was attempted but failed
due to the back proton transfer successfully competing with bimolecular
cycloadditions.”20

Scheme 1.7

13

Multiple diversity inputs can be introduced under these reaction conditions
(Scheme 1.8). Tethered alkenes, furan, and thiophene pendants proved to be reactive
dienophiles, as o-azaxylylenes act as acceptors in inverse electron demand
cycloadditions. The tether could be three to four atoms in length, respectively producing
five and six membered rings upon irradiation. Aldehydes, ketones, and cyclic ketones all
proved to be reactive.

Scheme 1.8 [Adopted From Angew. Chem. Int. Ed.20]

Photoprecursors showed broad UV absorption, with a maximum between 340-350
nm, and were irradiated using 365 nm Nichia UV LEDs or a Rayonet broadband 300-400
nm UV source yielding [4 + 2] and [4 + 4] isomers in most cases.20 An overview of the
first series of reactions run by Mukhina et al. can be seen in Scheme 1.9. Not only were
the products obtained in high overall yields, ranging from 60-89%, high
diastereoselectivity of the hydroxyl group relative to the bridged heteroatom was
observed in most cases. The anti diastereomer predominated in the [4 + 2]

14

cycloadditions while syn predominated in [4 + 4] cycloaddition, and in most cases
the diastereomeric ratio was 30:1 for the aldehydes.20

Scheme 1.9 [Adopted From Angew. Chem. Int. Ed.20]

It was postulated that this selectivity was the result of an endo transition state for
both the [4 + 2] and [4 + 4] cycloadditions (Scheme 1.10), where the resulting isomer is
dictated by the direction the hydroxyl group is facing in the transition state.20 Tetralone
is incapable of rotation at the carbonyl, and ketones are sterically hindered in the outhydroxy conformer and as a result show exclusive selectivity. Aldehydes show minor
15

amount of the unfavorable diastereomer, as they are less sterically hindered in the outhydroxy conformer when compared to the ketones.

Scheme 1.10 [Adopted From Angew. Chem. Int. Ed.20]

16

The research put forth in the following chapters of this dissertation sets out to
build upon the body of research by this initial discovery. In the following chapters,
evidence will be presented confirming that these cyclizations occur in the triplet excited
state in a stepwise fashion; that these photoproducts, and precursors can be modified in
keeping with the principle of diversity oriented synthesis; and build upon the
methodology by giving the first example of an excited state cascade reaction involving
two consecutively photogenerated o-azaxylylenes.

17

Chapter Two: Mechanistic Studies
Of all the things that I have accomplished at the University of Denver it is the
work in this chapter that I take the most pride in. Many novel compounds and diverse
libraries have come out of our lab, but this research was special to me because it was
about finding an answer. Understanding the underlying photophysics and
photochemistry behind excited state o-azaxylylene cycloadditions will optimize future
approaches to this methodology. However, this project felt like I was doing science for
science’s sake, and there is something special about doing something for its intrinsic
value.

Introduction
When Mukhina et al. published their initial work on photogenerated oazaxylylenes “a detailed photophysical mechanistic study of these cycloadditions [was]
ongoing;”20 however, there were some indications that the reaction occurred in a stepwise
fashion. First, concerted [4 + 2] cycloaddition is not allowed in the excited state, but
occurs upon coupling photogenerated o-azaxylylenes with tethered dienophiles, and the
only way that this can occur in the excited state is if the addition occurred in a stepwise
fashion. This is best demonstrated using frontier molecular orbital theory (Scheme 2.1),
where the highest occupied molecular orbital (HOMO) must share the same symmetry
18

with the lowest unoccupied molecular orbital (LUMO). If this process is concerted an
overlap in symmetry must occur for an overall net bonding interaction; however, there is
an asymmetrical overlap between the orbitals for [4 + 2] cyclization in the excited state
ruling out a concerted process. For clarity, the [4 + 4] cyclization is also depicted, which
is allowed in the excited state but forbidden in the ground state according to the frontier
molecular orbital theory.

19

Scheme 2.1

Another piece of evidence suggesting that the mechanism is not concerted was the
formation of disproportionation products (Scheme 2.2) that could only occur if the
reaction proceeded in a stepwise fashion. If the excited state o-azaxylylene is depicted as
a diradical, the mechanism can be initiated with an N-centered radical attack

20

on the double bond to form the initial 1,6-diradical, which can (i) rotate its
benzylic center and recombine to form the [4 + 2] adducts, or (ii) disproportionate
by H-abstraction to form benzylic alcohol with an N-acyl enamine moiety, which
undergoes subsequent ground state or photoinduced intramolecular alcohol
addition to yield aminal 2.1 (17%).20

Scheme 2.2 [Adopted From Angew. Chem. Int. Ed.20]

The following study was performed to elucidate the mechanism behind the
intramolecular cyclization of photogenerated o-azaxylylenes and was published in the
Journal of Physical Chemistry A.21 Quantum yields, quantum efficiency in the presence
of triplet quenchers, steady state spectroscopy, and time-correlated single photon
counting were used to provide a significant body of evidence that the excited state
intramolecular proton transfer (ESIPT) is followed by intersystem crossing (ISC) to the
triplet state, and stepwise addition to the tethered unsaturated pendant.
Results and Discussion
From a mechanistic standpoint, there are several potential pathways that
photogenerated o-azaxylylenes can take to yield intramolecular cycloaddition products
(Scheme 2.3). This pseudo Jablonski diagram does not depict the relative energies of
each species, but instead is designed to be a tool to help envision the possible routes that
21

can be taken to reach the cyclization products. The possibilities listed in Scheme 2.3 can
be ruled out systematically. Pathway 1 and 2 involve cycloaddition in the ground state,
and evidence will be presented against this process. Pathway 3 does not undergo
intersystem crossing (ISC), and can be eliminated by providing evidence that the reaction
proceeds through a triplet state. The final two pathways, 4 and 5, both proceed through a
triplet state and only differ where the excited state intramolecular proton transfer (ESIPT)
takes place, and this difference can be addressed through phosphorescence studies.22

22

Scheme 2.3

23

The first two potential pathways listed involve cycloaddition in the ground state,
and both can be addressed simultaneously. Pathway 1, involves a pure ground state
reaction leading to the cycloaddition products, and pathway 2 proceeds through excitation
to the first singlet excited state (S1), ESIPT, internal conversion to a ground state oazaxylylene, and cycloaddition. According to DFT calculations, there is no energy
barrier for the back proton transfer in the ground state (Figure 2.1), indicating that oazaxylylene formation in the ground state is not favorable as the cycloaddition process
could not compete with the rate of back proton transfer, ruling out pathway one. There is
an energy barrier for the back proton transfer in S1, so the lifetime of the o-azaxylylene
would be significantly greater in S1 than in the ground state. However, a ground state
cycloaddition mechanism after excitation, ESIPT, and internal conversion to the ground
state, pathway two, is unfavorable. Internal conversion of an o-azaxylylene from S1 to
the ground state would result in an immediate back proton transfer, as there is no energy
barrier in the ground state, which is significantly faster than the cycloaddition process.

24

Figure 2.1 [Adopted From J. Phys. Chem. A21]

Knowing that the cycloaddition takes place in the excited state, the next question
to answer is if the excited state species remains as a singlet, or undergoes intersystem
crossing (ISC) to a triplet state. Without ISC to the triplet state, the underlying process
could potentially proceed through excitation to S1, followed by ESIPT, cycloaddition, and
internal conversion to the ground state yielding the cycloaddition products, Pathway 3. A
significant body of evidence has been generated to leave little, if any, doubt that the
mechanism proceeds through a triplet state.
To start, the quantum efficiency of cyclization significantly decreases upon the
addition of known triplet quenchers, trans piperylene23 and molecular oxygen (Figure
2.2). Not only does this provide insight to the photochemical process, but allows for the
calculation of the excited state species lifetimes using Stern-Volmer analysis (KSV = 99
25

for quenching with O2 in acetonitrile, and KSV = 57 for quenching with trans-piperylene
in benzene). Assuming that the rate of quenching is diffusion controlled (Kdif = 1.0 x
1010 M-1 s in benzene, and 1.9 x 1010 in acetonitrile24), the lifetime of the excited triplet
state species for 2.1b was calculated to be approximately 5.2 ns in acetonitrile and 5.7 ns
in benzene.

Figure 2.2 [Adopted From J. Phys. Chem. A21]

Further evidence supporting a triplet state mechanism was provided by time
correlated single photon counting (TCSPC) experiments (Figure 2.3), which were
performed on o-azaxylylene photoprecursors bearing furan pendants (2.1a and 2.1b), and
their acetylated counterparts (2.11a and 2.11b). It is difficult to determine the identity of
each species. However, the results indicate that the addition of a furan pendant does not
have an effect on the rate of decay of fluorescence. If the mechanism proceeded through
26

a singlet state, the fluorescence lifetime of the ESIPT singlet state species would decrease
upon substituting the acetyl group with the furan pendant, as there would be an
alternative pathway taking away from the quantum yield (QY) of fluorescence. We do
not see this when comparing the furanpropanoylated and acetylated pairs, leading to the
conclusion that the reaction likely proceeds through a triplet state.

27

Figure 2.3 [Adopted From J. Phys. Chem. A21]

Additional evidence supporting a triplet state mechanism can be seen when
comparing the fluorescence spectrum of o-azaxylylene photoprecursors with differing
28

pendants and substitutions. o-Azaxylylenes produce two distinct bands, usually between
350 and 650 nm, where the blue shifted band represents the fluorescence of the excited
ketone or aldehyde where no ESIPT has taken place, and the red shifted band
representing that of the ESIPT species25. When comparing the fluorescence spectrum of
the aminotetralone derivative bearing a reactive furan pendant, 2.4a, to that of the
acylated species incapable of cycloaddition, 2.12a one can see that there is little
difference in the relative intensities between the two bands in the fluorescence spectra
(Figure 2.4). The rationale is similar to that in the TCSPC experiment: if there were a
cycloaddition channel in the singlet excited state then a decrease in fluorescence emission
of the red-shifted band should be observed for the species capable of cycloaddition, 2.4a,
when compared to that of the species incapable of cycloaddition, 2.12a. Solutions of
2.4a or 2.12a (1x10-5 M in DCM) were irradiated at 325 nm.

29

Figure 2.4 [Adopted From J. Phys. Chem. A21]

Halogen substitution in the aromatic ring produces a significant change in the
ratio between the fluorescence intensity of the two bands. This can be seen when
comparing the tetralone derivative bearing a reactive furan pendant (2.4a) to the same
species with a bromo substitution in the para position (2.2b, Figure 2.5). Heavy atoms,
in this case bromine, have a high nuclear charge and cause electrons to accelerate as they
pass by the nucleus increasing the rate of spin-orbit coupling-induced transitions, which
is necessary for intersystem crossing (ISC) from a singlet to a triplet state.24 This
phenomenon, dubbed the “heavy atom effect,” manifests itself in Figure 2.5 as a
decrease in the fluorescence intensity of the ESIPT band upon bromo substitution that
results from an increased quantum yield of ISC.
30

Figure 2.5 [Adopted From J. Phys. Chem. A21]

An absolute quantum yield study was performed on a library of o-azaxylylene
photoprecursors using a benzophenone-benzhydrol actinometer26 (Figure 2.6). Solutions
of the photoprecursor (1x10-2 M) in acetonitrile were thoroughly degassed with N2,
irradiated on a carrousel using 365 nm Nichia UV LEDs along with the actinometer, and
the formation of the [4 + 2] and [4 + 4] cycloaddition products in the samples being
tested, as well as the formation of pinacol in the actinometer were monitored by 1H
NMR. In keeping with the heavy atom effect, photoprecursors containing halogen
substituents had significantly greater quantum yields than their non-halogenated
counterparts. Substitution at the carbonyl impeded the cycloaddition process, which can
be attributed to the stabilized hydroxybenzylic radical being less reactive.
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Figure 2.6 [Adopted From J. Phys. Chem. A21]

The greatest quantum yield in the series was the aminobenzaldehyde derivative
containing a bromo substitution at the 5 position (Φr = 0.75), which showed greater
efficiency than that of 5-iodo (Φr = 0.54) and 5-chloro (Φr = 0.32) substitutions. This
series illustrates that there is an interplay between the heavy atom effect on spin-orbit
coupling (SOC) and the effect of electron withdrawing substituents enhancing the
reactivity of the N-centered radical towards the electron rich diene of the furan pendant.
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Pauling electronegativities, atomic SOC values, and the quantum yield (Φr) of
cycloaddition are compiled in Table 2.1 for this series. Iodo substitution provides
sufficient SOC but shows low electronegativity, while choloro substitution displays the
inverse. Bromine lies in the middle when it comes to SOC and electronegativity, which
may explain the higher Φrs compared to the other compounds in the series.

Cl

Br

I

Electronegativity

3.16

2.96

2.66

Atomic SOC cm-1

587

2460

5069

QY, cycloaddition

0.32
(2.1d)

0.75
(2.1b)

0.54
(2.1c)

Table 2.1 [Adopted From J. Phys. Chem. A21]

The preceding body of evidence shows that the cycloaddition of o-azaxylylenes
proceeds through a triplet state, eliminating pathways 1-3; however, this leaves two
possible scenarios. ESIPT could potentially occur in the singlet (Pathway 4) or triplet
state (Pathway 5). It has been established that ESIPT does not occur in the triplet state,
as the two phosphorescence bands of the triplet 2-aminobenzophenone conformers, one
being the EISPT species and the other being the ketone, decay independently of one
another22 leaving pathway 4 as the only remaining excited state pathway. To conclude,
the mechanism proceeds through excitation to the singlet state, where ESIPT takes place,
followed by ISC, radical addition of the N-centered radical resulting in a ground state
species where the final radical recombination occurs yielding the cycloaddition products
(Scheme 2.4).
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Scheme 2.4

*The spectra and synthetic procedures for the materials presented in this Chapter
are given in the experimental section of Chapter 3, as the materials used in this
study are a subset of those synthesized in the following chapter.
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Chapter 3: Postphotochemical Modifications
The mechanistic studies in the previous chapter have provided insight into the
process of o-azaxylylene cycloaddition and allow those utilizing this chemistry to do so
optimally. Moving forward, the next topic to address would be whether these novel
scaffolds are amenable to postphotochemical modifications to the overall topology and
probe unexplored regions of chemical space. The research in this chapter was published
in the Journal of Organic Chemistry.12

Introduction
Combinatorial chemistry and diversity oriented synthesis are valuable tools, as
they are capable of producing large libraries of compounds efficiently.9 It has been
shown that o-azaxylylene cycloadditions are capable of producing significantly diverse
frameworks and adhere to the fundamentals of diversity oriented synthesis.20 Further
modification of the scaffold can yield structures reminiscent of natural products, and
expands the area of chemical space explored.9 According to an extensive study by
Roughley and Jordan,27 Suzuki coupling accounts for 40% of all C-C bond forming
reactions, and sp2-sp2 coupling is one of the most commonly used reactions by medicinal
chemists in the pursuit of drug candidates. Suzuki coupling holds other advantages that
serve as a good starting point for postphotochemical modification, in that there are many
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boronic acids commercially available, and the procedures are well documented. This
study sets out to explore the modification of these cycloaddition adducts using Suzuki
coupling.

Results and Discussion
To incorporate Suzuki coupling into the synthesis of the cycloaddition scaffolds
two coupling approaches were explored (Scheme 3.1): pre-photochemical coupling of the
heteroboronic acid with the halogen-substituted photoprecursor (path a), and postphotochemical coupling of the cycloaddition products (path b). This was the first goal of
the study, as extended conjugation could potentially affect the photoefficency.
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Scheme 3.1 [Adopted From J. Org. Chem12]

Synthesis of 3.1a was accomplished by acylating the 5-bromophenylmethanol
with 2-furanpropanoyl chloride, and the product was then either subjected to Suzuki
coupling followed by PCC oxidation, and irradiation (path a) or oxidized by PCC then
irradiated and coupled to the aryl boronic acid (path b). Both the halogen (3.3a), and
hetroaryl (3.3b) photoprecursors were irradiated with a Rayonet broadband 300-400 nm
UV source, and the optimal solvent for irradiation was determined to be 5% aqueous
acetonitrile. Irradiation of both photoprecursors yielded one diastereomer of the [4 + 2]
(syn) and [4 + 4] (anti) cycloaddition products in an approximate ratio of 1:1, where syn
and anti refer to the relative position of the bridged oxygen and the hydroxyl group.
Suzuki coupling of the photoproducts resulted in some degradation of the [4 + 2] product.
The yields were comparable for both pathway a and b, 44% and 35% respectively.
However, the quantum efficiency differed considerably between photoprecursors 3.3a
and 3.3b, being 3.7 times greater for the halogen substituted precursor (3.3a) utilized in
pathway b, the reasoning being explained in Chapter 2. Given the similar overall yields,
it was decided to follow path b to probe the scope of the reaction due to the increased
quantum efficiency.
In keeping with the principles of DOS, a modular approach was implemented to
gain access to a diverse array of photoprecursors. Modifications to the halogen and its
position in the aromatic ring, the linker connecting the 2-acylaniline to the furan pendant,
and the substituent on the carbonyl were employed yielding the compounds seen in Table
3.1.
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o-Formyl- or
o-acyl-aniline

Linker

39
Isolated yields of photoprecursors are given

Table 3.1 [Adopted From J. Org. Chem12]

Photoprecursors 3.3a-e, 3.9, and 3.12-16 were synthesized according to Scheme
3.2 and 3.3. Halogen substituted alcohols 3.7a, c-e, 3.8 and ketones 3.10, 3.11 were
acylated with furanpropanoyl chloride 3.6. After acylation, ketones 3.12 and 3.13 were
irradiated, while alcohols were oxidized using PCC to yield photoprecursors 3.3a, c-e.
Halogen-substituted methyl anthranilates were coupled in the same fashion, reduced with
LiAlH4, and oxidized using PCC.

Scheme 3.2 [Adopted From J. Org. Chem12]

Diversification of the linker was achieved using a peptoid synthesis-inspired28,29
approach with bromoacetyl bromide (Scheme 3.3). Bromoacylation of alcohol 3.7a or
ketone 3.11 was followed by the addition of furfuryl or benzyl amine, and subsequent
acylation with either pivaloyl or furoyl chloride, respectively. The alcohol was then
oxidized using PCC.
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Scheme 3.3 [Adopted From J. Org. Chem12]

The products synthesized from photochemical cyclization and subsequent Suzuki
coupling are presented in Scheme 3.4, and the yields can be found in Table 3.2. In all
cases irradiation produced both the [4 +2] in [4 + 4] cycloaddition products with good
diastereoselectivity, and on average the irradiations were complete in less than 5 hours.
The mixture of cycloaddition products were subjected to Suzuki coupling to yield the
fused biaryls and purified by column chromatography. Palladium-catalyzed cross
coupling proved to be sensitive to the addition of heteroatoms in the linker, as
demonstrated in two of the three cases where the peptoid-inspired methodology was
employed. In these instances, Suzuki coupling resulted in the complete degradation of [4
+ 2] cycloaddition products bringing the yield below 40%.
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Scheme 3.4 [Adopted From J. Org. Chem12]

Photoprecursor Photoproducts
ratio [4+2]:[4+4]a
3.3a

3.4a:3.5a = 1:1

3.3d

3.4d:3.5d = 1:1

3.9
3.12
3.13
3.14
3.15
3.16

3.17a:3.18a = 1:0.8
3.19a:3.20a = 1:1.1
3.21a:3.22a = 1:1.9
3.23a:3.24a = 1:1.4
3.25a:3.26a = 1:1.5
3.27a:3.28a = 1:16

Suzuki coupling
Suzuki coupling
product from [4+2]b product from
[4+4]b
3.4f, 30%
3.5f, 44%
3.4b, 7%
3.5b, 28%
3.4g, 17%
3.5g, 26%c
3.4h, 27%
3.5h, 39%
3.17b, 30%
3.18b, 24%
3.19b, 28%
3.20b, 30%
3.21b, 36%
3.22b, 16%
3.23b 19%
3.24b, 12%
3.25b, -3.26b, 20%
3.27b, -3.28b, 36%

a

Determined by NMR of the reaction mixture after completion of irradiation. For [4 + 4] the
double bond proton at approximately 6.4 ppm (dd, J = 6.0, 2.0 Hz, 1H), and for [4 + 2] the
double bond proton at approximately 6.3 ppm (t, 2.8 Hz, 1H); bisolated yields; cthe primary [4+4]
photoproduct rearranges from the bicyclo[4.2.1] to bicyclo[3.3.1] framework.

Table 3.2 [Adopted From J. Org. Chem12]

Coupling conditions were dependent on the boronic acid being used. The catalyst
of choice for coupling with 3-pyridine boronic acid was Pd2(dba)3 (0.9 mol %) using
PCy3 as a ligand, while 2-furyl and 2-thienyl boronic acids were coupled with
Pd(PPh3)4 (5 mol %). Bromine substituted substrates were reactive with 3-pyridine
boronic acids; however, thienyl and furyl boronic acids required iodine substituted
substrates. All attempts using MIDA30 boronates failed. X-Ray analysis was performed
on crystalline products unambiguously proving their structure and stereochemistry (see
experimental).
Additionally, a rearrangement from the bicyclo [4.2.1] to a bicyclo [3.3.1] skeletal
structure was observed when 3.5g was subjected to silica during chromatography
(Scheme 3.5), which results from ring opening and closure of the [4 + 4] photo product.
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It was found that heating the [4 + 4] cycloaddition in DMSO also produces the [3.3.1]
rearrangement product.

Scheme 3.5 [Adopted From J. Org. Chem12]

Since this research was published back in 2014, other novel post photochemical
modifications have been implemented demonstrating the synthetic utility of these
cycloaddition products. For example, Umstead et al. illustrated that the alkene generated
from photochemical cycloaddition was reactive to 1,3-dipoles, and N-phenyl-aryl-2ylmethanimines15 (Scheme 3.6), yielding an array of products with significantly diverse
core scaffolds.
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Scheme 3.6

Given the growing body of data regarding the synthetic utility of photogenerated
o-azaxylylenes it is clear that this methodology of producing fused ring systems is
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aligned with the principles of DOS. These reactions show a high degree of
diastereoselectivity, produce unprecedented fused ring systems, and are amenable to
postphotochemical modifications.

Experimental
Common solvents were purchased from Pharmco and used as is, except for THF,
which was refluxed over and distilled from potassium benzophenone ketyl prior to use.
Common reagents were purchased from Aldrich or TCI America and used without
additional purification, unless indicated otherwise. NMR spectra were recorded at 25°C
on a Bruker Avance III 500 MHz in CDCl3 with TMS as an internal standard (unless
noted otherwise) High resolution mass spectra were obtained on the MDS SCIEX/Applied
Biosystems API QSTARTM Pulsar i Hybrid LC/MS/MS System mass spectrometer by Dr.
Shuji Kato and Dr. Dan Gu at the University of Colorado at Boulder. Flash column
chromatography was performed using Teledyne Ultra Pure Silica Gel (230 – 400 mesh)
on a Teledyne Isco Combiflash Rf using Hexanes/EtOAc or DCM/Methanol as an eluent.

2-Furanpropanoyl chloride31 (3.6): To a stirred solution of 3-(2furyl)propanoic acid (1 eq, 1.15 g, 8.2 mmol) in 15 mL of DCM was
added SOCl2 (1.3 eq, 0.79 mL, 11 mmol). The solution was refluxed for 4 hours, allowed
to cool to room temperature, and concentrated, yielding 1.28 g (99%) of the product. 1H
NMR (500 MHz, CDCl3) δ 7.35 (dd, J = 1.9, 0.9 Hz, 1H), 6.32 (dd, J = 3.2, 1.9 Hz, 1H),
6.10 (m, 1H), 3.27 (t, J = 7.3 Hz, 2H), 3.07 (t, J = 7.3 Hz, 2H).
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Synthesis of halogen-substituted o-hydroxymethylanilines and o-acetylanilines

Methyl 2-amino-4-bromobenzoate32 (S1): To an ice cooled solution
of 4-bromo-2-nitrobenzoic acid (1.50 g, 6.10 mmol) in DMF (15
mL) was added DBU (8.3 mL, 55 mmol), followed by the addition of
MeI (3.4 mL, 54.9 mmol). The reaction was allowed to stir overnight, poured into water
(30 mL), extracted with EtOAc (4 x 75 mL), dried over Na2SO4, filtered and concentrated
yielding 1.54 g (97%) of methyl 4-bromo-2-nitrobenzoate. 1H NMR (500 MHz,
CDCl3) δ 8.03 (d, J = 1.9 Hz, 1H), 7.83 (dd, J = 8.2, 1.9 Hz, 1H), 7.67 (d, J = 8.2 Hz,
1H), 3.93 (s, 3H). To a solution of methyl 4-bromo-2-nitrobenzoate (1.52 g, 5.85
mmol) in a 1:1 mixture of EtOAc and DCM (12 mL) was added SnCl2∙2H2O (6.18 g,
27.4 mmol). After 24 hours the mixture was concentrated, diluted with a solution of sat.
aq. NaHCO3, extracted with DCM, and concentrated yielding 1.15g (82%) of the title
compound over two steps. 1H NMR (500 MHz, CDCl3) δ 7.72 (d, J = 8.6 Hz, 1H), 6.87
(d, J = 1.9 Hz, 1H), 6.78 (dd, J = 8.6, 1.9 Hz, 1H), 5.81 (s, 2H), 3.88 (s, 3H).

13

C NMR

(126 MHz, CDCl3) δ 168.1, 151.2, 132.6, 128.7, 119.5, 119.0, 109.6, 51.7.

2-Amino-5-bromobenzyl alcohol33 (S2): Methyl 2-amino-5bromobenzoate (3.00 g, 13.0 mmol) in THF (9 mL) under nitrogen
atmosphere was cooled to -41 °C using a acetonitrile/CO2 (s) cooling
bath, and DIBAL-H (39.1 mL of a 1.0 M solution in hexanes, 43.0 mmol) was slowly
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added to the stirred solution. After maintaining at -41 °C for 1.5 hours, the solution was
allowed to reach room temperature and left to stir overnight. The solution was cooled in
an ice water bath, quenched by the addition of methanol, a solution of sat. aq. sodium
potassium tartrate was added, and the mixture was allowed to stir for 30 min. The
organic phase was extracted with Et2O (3 x 100 mL), and concentrated yielding 2.41 g
(92%) of the product. 1H NMR (500 MHz, CDCl3) δ 7.24 (m, 2H), 6.61 (d, J = 8.3 Hz,
1H), 4.66 (d, J = 4.5 Hz, 2H), 4.22 (s, 2H).

4-Bromo-2-((trimethylsilyl)methyl)aniline (S3):
Chlorotrimethylsilane (1.16 mL, 9.14 mmol) was added to a stirred
solution of 2-amino-5-bromobenzyl alcohol (1.68 g, 8.33 mmol)
and triethylamine (2.32 mL, 16.6 mmol) in DCM (70 mL). The reaction mixture was
stirred at room temperature overnight. The mixture was quenched with a solution of sat.
aq. NH4Cl (50 mL), the organic layer was separated, and the aqueous phase was extracted
with DCM (3 x 100 mL). The organic fractions were combined, dried over Na2SO4,
filtered, and concentrated yielding 2.35 g (94%) of the product. 1H NMR (500 MHz,
CDCl3) δ 7.19 (m, 2H), 6.57 (d, J = 8.2 Hz, 1H), 4.61 (s, 2H), 4.18 (s, 2H), 0.16 (s, 9H).

2-Amino-4-bromobenzyl alcohol34 (S4): Methyl 2-amino-4bromobenzoate (1.14 g, 4.95 mmol) in THF (5.5 mL) under nitrogen
atmosphere was cooled to -41 °C. DIBAL-H (16.35 mL of a 1.0 M
solution in hexanes, 16.35 mmol) was slowly added to the stirred solution. After
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remaining at -41 °C for 1.5 hours, the solution was allowed to reach room temperature
and left to stir overnight. The solution was cooled in an ice water bath, quenched by the
addition of methanol (35 mL), a solution of sat. aq. sodium potassium tartrate was added
(70 mL), and the mixture was allowed to stir for 6 hours. The organic phase was
extracted with Et2O (3 x 125 mL), and concentrated yielding 0.98 g of (2-amino-4bromophenyl)methanol which was used without further purification. 1H NMR (500
MHz, CDCl3) δ 6.95 (d, J = 7.9 Hz, 1H), 6.88 (d, J = 1.9 Hz, 1H), 6.85 (dd, J = 7.9, 1.9
Hz, 1H), 4.66 (d, J = 5.1 Hz, 2H), 4.29 (s, 2H), 1.54 (m, 1H).

5-Bromo-2-((trimethylsilyloxy)methyl)aniline (S5):
Chlorotrimethylsilane (0.69 mL, 5.4 mmol) was added to a stirred
solution of (2-amino-4-bromophenyl)methanol (0.98 g 4.9 mmol) and triethylamine
(1.36 mL, 9.75 mmol) in DCM (43 mL). The reaction mixture was stirred at room
temperature overnight. The mixture was quenched with a solution of sat. aq. NH4Cl (70
mL), the organic layer was separated, and the aqueous phase was extracted with DCM (3
x 100 mL). The organic fractions were combined, dried over Na2SO4, filtered, and
concentrated yielding 1.11 g of 5-bromo-2-((trimethylsilyloxy)methyl)aniline which was
used without further purification. 1H NMR (500 MHz, CDCl3) δ 6.90 (d, J = 7.8 Hz, 1H),
6.84 (d, J = 1.8 Hz, 1H), 6.82 (dd, J = 7.8, 1.9 Hz, 1H), 4.61 (s, 2H), 4.26 (s, 2H), 0.14 (s,
9H).
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2-Amino-5-iodobenzyl alcohol35 (S6): Methyl 5-iodoanthranilate
(3.00 g, 10.8 mmol) in THF (7.5 mL) under nitrogen atmosphere was
cooled to -41 °C. DIBAL-H (32.7 mL of a 1.1 M solution in
cyclohexane, 36 mmol) was slowly added to the stirred solution. After remaining at -41
°C for 1.5 hours, the solution was allowed to reach room temperature and left to stir
overnight. The solution was cooled in an ice water bath, quenched by the addition of
methanol, a solution of sat. aq. sodium potassium tartrate was added, and the mixture was
allowed to stir for 30 min. The organic phase was extracted with Et2O (3 x 100 mL), and
concentrated yielding 2.48 g (92%) of the product. 1H NMR (500 MHz, CDCl3) δ 7.41
(dd, J = 8.3, 2.2 Hz, 1H), 7.39 (d, J = 2.1 Hz, 1H), 6.51 (d, J = 8.3 Hz, 1H), 4.64 (d, J =
5.3 Hz, 2H), 4.24 (s, 2H).

4-Iodo-2-((trimethylsilyloxy)methyl)aniline (S7):
Chlorotrimethylsilane (0.49 mL, 3.8 mmol) was added to a stirred
solution of 2-amino-5-iodobenzyl alcohol (0.87 g, 3.5 mmol) and
triethylamine (0.98 mL, 7.0 mmol) in DCM (32 mL). The reaction mixture was stirred at
room temperature overnight. The mixture was quenched with a solution of sat. aq.
NH4Cl (50 mL), the organic layer was separated, and the aqueous phase was extracted
with DCM (3 x 100 mL). The organic fractions were combined, dried over Na2SO4,
filtered, and concentrated yielding 0.94 g (83%) of the product. 1H NMR (500 MHz,
CDCl3) δ 7.37 (dd, J = 8.2, 2.2 Hz, 1H), 7.35 (d, J = 2.1 Hz, 1H), 6.47 (d, J = 8.3 Hz,
1H), 4.59 (s, 2H), 4.21 (s, 2H), 0.15 (s, 9H).
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1-(2-amino-5-bromophenyl)ethanone36 (3.7): 2’Aminoacetophenone (10 g, 73.96 mmol) was dissolved in Ac2O, stirred
for 2 hours and concentrated. The residue was then dissolved in DCM,
treated with Br2 (6 mL), allowed to stir for 3 hours, quenched with water, filtered, and the
collected solid was washed with water. The solid residue was transferred to a round
bottomed flask, dissolved in 2 M HCl (200 mL), and the solution was heated at 90 °C for
4 hours. The solution was allowed to reach room temperature, basified to pH 12,
extracted with EtOAc (3 x 50 mL), dried over Na2SO4, and concentrated yielding 13.5 g
(85%) of the product. 1H NMR (500 MHz, CDCl3) δ 7.82 (s, 1H), 7.35 (d, J = 8.8 Hz,
1H), 6.58 (d, J = 8.8, 0.9 Hz, 1H), 6.32 (s, 2H), 2.58 (s, 3H).

13

C NMR (126 MHz,

CDCl3) δ 199.6, 149.1, 137.0, 134.1, 119.4, 119.0, 106.6, 27.8.

N-(4-bromo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide37 (S8):
5,6,7,8-Tetrahydro-1- naphthylamine (3.0 mL, 21.6 mmol) in EtOH (10
mL) was added dropwise to an ice-cooled solution of acetic anhydride
(4.08 mL, 43.2 mmol) in EtOH (40 mL). The mixture was stirred for 16
hours at room temperature. Subsequently, the solvent was removed under reduced
pressure to yield N-(5,6,7,8- tetrahydro-1-naphthyl)-acetamide as a white solid which
was used without further purification 1H NMR (500 MHz, CDCl3) δ = 7.63 (d, J=7.9,
1H), 7.15 (t, J=7.8, 1H), 6.95 (d, J=7.5, 1H), 6.89 (s, 1H), 2.81 (m, 2H), 2.62 (m, 2H),
2.23 (s, 3H), 1.87 (m, 2H), 1.80 (m, 2H). To a cooled solution of N-(5,6,7,851

tetrahydro-1-naphthyl)-acetamide in AcOH (55 mL) was slowly added a solution of
Br2 (3.36 mL, 65.2 mmol) in AcOH (4 mL) so that the temperature remained below 17
°C. The reaction mixture was then allowed to stir at room temperature for 24 hours. The
mixture was poured over ice water, the resulting suspension was filtered, and the
collected solid was washed with water. The solid was dissolved in DCM (200 mL) and
H2O (50 mL), the organic phase was separated, and the aqueous phase was extracted with
DCM (3 x 100 mL). The organic phases were combined, dried over Na2SO4, filtered, and
concentrated yielding 6.98 g (99.6%) of the product. 1H NMR (500 MHz, CDCl3) δ 7.53
(d, J = 8.6 Hz, 1H), 7.43 (d, J = 8.6 Hz, 1H), 6.89 (s, 1H), 2.77 (m, 2H), 2.61 (m, 2H),
2.24 (s, 3H), 1.81 (m, 4H).

N-(4-Bromo-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide (S9):
N-(4-bromo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide (3.09 g, 11.5
mmol) in acetone (80 mL) and 15% aqueous MgSO4 (1.90 g, 15.8 mmol
in 11 mL of H2O) was treated with KMnO4 (5.47 g, 34.6 mmol) in
portions. The mixture was allowed to stir for 12 hours, filtered through Celite®, and the
solids were washed with CHCl3 (100 mL) and H2O (100 mL). The aqueous layer was
extracted with CHCl3 (4 x 100 mL). The organic fractions were combined, washed with
brine, and dried over Na2SO4, and concentrated yielding 1.90 g (58.6%) of the desired
product. 1H NMR (500 MHz, CDCl3) δ 12.16 (s, 1H), 8.58 (d, J = 9.1 Hz, 1H), 7.72 (d, J
= 9.1 Hz, 1H), 3.06 (t, J = 6.2 Hz, 2H), 2.72 (m, 2H), 2.25 (s, 3H), 2.14 (m, 2H).
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8-Amino-5-bromo-3,4-dihydronaphthalen-1(2H)-one (3.8): A stirred
solution of N-(4-bromo-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide
(1.90 g, 6.74 mmol) in 6M HCl (100 mL) was heated at 90 °C for 8 hours.
The mixture was cooled to room temperature and the volatiles were removed under
vacuum. Ice was added to the mixture, followed by 2M NaOH until pH of 8 was reached.
The aqueous layer was extracted with EtOAc, the organic fractions were combined,
washed with brine, dried, filtered, and the concentrated to give 1.26 g of the product
(77.9%). 1H NMR (500 MHz, CDCl3) δ 7.39 (d, J = 8.9 Hz, 1H), 6.55 (s, 2H), 6.43 (d, J
= 8.8 Hz, 1H), 2.96 (t, J = 6.2 Hz, 2H), 2.65 (m, 2H), 2.08 (m, 2H).

Photoprecursors synthesis

General procedure for the reaction of 2-furanpropanoyl chloride with
amines (FC): A crude solution of 2-furanpropanoyl chloride (1.2 -1.5 eq) in dry THF
(25 mL) was added dropwise to an ice-cooled stirred solution of substituted anilines (1
eq) and anhydrous pyridine (1.1 eq) in THF (50 mL). The solution was allowed to reach
room temperature and left to stir overnight. The reaction mixture was then diluted with
water (100 mL), extracted with EtOAc (4 x100 mL), the combined organic fractions were
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washed with 10% NaOH (100 mL), dried over Na2SO4, filtered, and concentrated. The
product was purified when necessary using flash chromatography.

General procedure for the synthesis of and N-(2-acetylphenyl)-2bromoacetamides (BB): Bromoacetyl bromide (1.1 eq) in dry DCM (10 mL) was slowly
added to a stirred solution of amine (1 eq), pyridine (1.1 eq) in dry DCM (20 mL) at 0oC
under nitrogen atmosphere. The reaction mixture was left stirring overnight, then it was
quenched with water (10 mL) and the aqueous phase was extracted with DCM (2x75
mL). Combined organic layers were dried over Na2SO4 and concentrated, giving the
crude product, which was used further without purification.

N-(4-chloro-2-formylphenyl)-3-(furan-2yl)propanamide (3.3c): General procedure FC was
followed using 2-furanpropanoyl chloride (6) (0.51 g, 3.2
mmol, 1 eq), 2-amino-5-chlorobenzyl alcohol (0.50 g, 3.2 mmol, 1 eq) and anhydrous
pyridine (0.28 mL, 3.5 mmol) in THF (10 mL). The workup and purification by flash
chromatography yielded 0.67 g (2.4 mmol, 75%) of N-(4-chloro-2(hydroxymethyl)phenyl)-3-(furan-2-yl)propanamide. 1H NMR (500 MHz, CDCl3) δ
8.45 (s, 1H), 8.03 (d, J = 8.7 Hz, 1H), 7.36 (m, 1H), 7.31 (dd, J = 8.7, 2.4 Hz, 1H), 7.20
(d, J = 2.4 Hz, 1H), 6.32 (t, J = 2.4 Hz, 1H), 6.11 (d, J = 3.2 Hz, 1H), 4.62 (d, J = 4.5 Hz,
2H), 3.11 (t, J = 7.4 Hz, 2H), 2.77 (t, J = 7.4 Hz, 2H), 2.07 (s, 1H). To a stirred solution
of N-(4-chloro-2-(hydroxymethyl)phenyl)-3-(furan-2-yl)propanamide (0.67 g, 2.4
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mmol) in dry DCM (100 mL) was added PCC (0.78 g, 3.6 mmol). The reaction mixture
was left stirring overnight, filtered through a layer of silica gel, and evaporated yielding
0.64 g (2.3 mmol, 54% over two steps) of the title compound. 1H NMR (500 MHz,
CDCl3) δ 11.08 (s, 1H), 9.88 (d, J = 0.7 Hz, 1H), 8.77 (d, J = 9.0 Hz, 1H), 7.66 (d, J = 2.5
Hz, 1H), 7.58 (dd, J = 9.1, 2.5 Hz, 1H), 7.34 (dd, J = 1.9, 0.9 Hz, 1H), 6.30 (dd, J = 3.2,
1.9 Hz, 1H), 6.09 (m, 1H), 3.11 (m, 2H), 2.84 (m, 2H).

13

C NMR (126 MHz, CDCl3) δ

194.3, 171.2, 153.8, 141.3, 139.3, 136.0, 135.0, 128.0, 122.5, 121.6, 110.2, 105.6, 36.5,
23.6.

Methyl 5-bromo-2-(3-(furan-2-yl)propanamido)benzoate
(S10): General procedure FC was followed using 2furanpropanoyl chloride (1.2 eq, 1.67 g, 10.5 mmol), methyl
2-amino-5-bromobenzoate (1 eq, 2.00 g, 8.6 mmol) and
anhydrous pyridine (1.1 eq, 0.76mL, 9.5mmol). The workup yielded 3.00 g (99%) of the
product. 1H NMR (500 MHz, CDCl3) δ 11.05 (s, 1H), 8.68 (d, J = 9.1 Hz, 1H), 8.17 (d, J
= 2.5 Hz, 1H), 7.65 (dd, J = 9.1, 2.5 Hz, 1H), 7.33 (dd, J = 1.9, 0.8 Hz, 1H), 6.29 (dd, J =
3.2, 1.9 Hz, 1H), 6.09 (m, 1H), 3.96 (s, 3H), 3.11 (m, 2H), 2.81 (m, 2H). 13C NMR (126
MHz, CDCl3) δ 170.7, 167.6, 154.0, 141.3, 140.5, 137.4, 133.3, 122.1, 116.4, 114.8,
110.2, 105.5, 52.7, 36.7, 23.7.
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N-(4-Bromo-2-formylphenyl)-3-(furan-2-yl)propanamide
(3.3a): To a suspension of LiAlH4 (0.88 g, 23 mmol) in THF
(12 mL) at -78 °C under nitrogen atmosphere was added
methyl 5-bromo-2-(3-(furan-2-yl)propanamido)benzoate (4.29 g, 12.2 mmol)
dissolved in THF (24 mL). The mixture was allowed to stir overnight, treated with water
(1 mL), 10% NaOH (1 mL), followed by an additional allotment of water (3 mL), and
dried over Na2SO4. The solvent was filtered and concentrated yielding 3.52 g of N-(4bromo-2-(hydroxymethyl)phenyl)-3-(furan-2-yl)propanamide which was used
without further purification. 1H NMR (500 MHz, CDCl3) δ 8.50 (s, 1H), 7.98 (d, J = 8.7
Hz, 1H), 7.45 (dd, J = 8.7, 2.4 Hz, 1H), 7.35 (m, 2H), 6.32 (dd, J = 3.1, 1.9 Hz, 1H), 6.11
(m, 1H), 4.61 (s, 2H), 3.10 (t, J = 7.4 Hz, 2H), 2.76 (t, J = 7.4 Hz, 2H), 2.21 (s, 1H).

13

C

NMR (126 MHz, CDCl3) δ 170.4, 154.0, 141.3, 136.4, 131.9, 131.5, 131.4, 124.2, 116.9,
110.4, 105.8, 63.8, 36.2, 24.0. To the alcohol (3.52 g) in dry DCM (250 mL) was added
PCC (2.63 g, 12.2 mmol). The reaction mixture was left stirring overnight, filtered
through a layer of silica gel, and evaporated yielding 2.11 g (53%) of the product over
two steps. 1H NMR (500 MHz, CDCl3) δ 11.08 (s, 1H), 9.87 (s, 1H), 8.72 (d, J = 8.9 Hz,
1H), 7.80 (d, J = 2.4 Hz, 1H), 7.72 (dd, J = 9.0, 2.4 Hz, 1H), 7.34 (dd, J = 1.9, 0.9 Hz,
1H), 6.30 (dd, J = 3.2, 1.9 Hz, 1H), 6.09 (m, 1H), 3.11 (m, 2H), 2.84 (m, 2H).

13

C NMR

(126 MHz, CDCl3) δ 194.2, 171.2, 153.8, 141.3, 139.8, 138.9, 138.0, 122.9, 121.9, 115.0,
110.2, 105.6, 36.5, 23.6. HRMS (ESI) calcd for C14H13BrNO3+ (MH+) 322.0073, found
322.0067.
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N-(5-bromo-2-formylphenyl)-3-(furan-2yl)propanamide (3.9): General procedure FC was
followed using 2-furanpropanoyl chloride (0.90 g, 5.7
mmol), 5-bromo-2-((trimethylsilyloxy)methyl)aniline (1.11 g, 4.05 mmol) and
anhydrous pyridine (0.49 mL, 6.1 mmol). Upon workup 1.27 g of N-(5-bromo-2(hydroxymethyl)phenyl)-3-(furan-2-yl)propanamide was isolated, which was used
without further purification. 1H NMR (500 MHz, CDCl3) δ 8.68 (s, 1H), 8.31 (d, J = 1.2
Hz, 1H), 7.35 (dd, J = 1.9, 0.9 Hz, 1H), 7.20 (dd, J = 8.1, 2.2 Hz, 1H), 7.02 (d, J = 8.1
Hz, 1H), 6.32 (dd, J = 3.2, 1.9 Hz, 1H), 6.10 (m, 1H), 4.60 (s, 2H), 3.08 (m, 2H), 2.75
(m, 2H). To N-(5-bromo-2-(hydroxymethyl)phenyl)-3-(furan-2-yl)propanamide
(1.27 g, 3.71 mmol) in DCM (90 mL) was added PCC (4.80 g, 22.3 mmol). The reaction
mixture was left stirring for 12 h, filtered through a layer of silica gel using EtOAc,
concentrated, and the mixture was subjected to flash chromatography yielding 0.40 g
(24%) of the product over four steps. 1H NMR (500 MHz, CDCl3) δ 11.22 (s, 1H), 9.89
(s, 1H), 9.05 (d, 1H), 7.53 (d, J = 8.2 Hz, 1H), 7.39 (dd, J = 8.2, 1.8 Hz, 1H), 7.34 (dd, J
= 1.9, 0.9 Hz, 1H), 6.30 (dd, J = 3.2, 1.9 Hz, 1H), 6.10 (m, 1H), 3.11 (m, 2H), 2.84 (m,
2H).

13

C NMR (126 MHz, CDCl3) δ 194.6, 171.3, 153.8, 141.4, 141.3, 136.8, 131.9,

126.3, 123.0, 120.2, 110.2, 105.6, 36.4, 23.5. HRMS (ESI) calcd for C14H13BrNO3+
(MH+) 322.0073, found 322.0080.
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N-(2-Formyl-4-iodophenyl)-3-(furan-2-yl)propanamide
(3.3d): General procedure FC was followed using 2furanpropanoyl chloride (0.79 g, 5.0 mmol), 4-iodo-2((trimethylsilyloxy)methyl)aniline (0.94 g, 2.9 mmol) and dry
pyridine (0.40 mL, 5.0 mmol) in THF (10 mL). Upon workup 0.90 g of N-(4-iodo-2(hydroxymethyl)phenyl)-3-(furan-2-yl)propanamide was isolated which was used
without further purification. 1H NMR (500 MHz, CDCl3) δ 8.50 (s, 1H), 7.89 (d, J = 8.5
Hz, 1H), 7.65 (dd, J = 8.6, 2.1 Hz, 1H), 7.53 (d, J = 2.2 Hz, 1H), 7.36 (dd, J = 1.9, 0.9 Hz,
1H), 6.32 (dd, J = 3.2, 1.9 Hz, 1H), 6.10 (m, 1H), 4.60 (d, J = 5.7 Hz, 2H), 3.10 (t, J = 7.4
Hz, 2H), 2.76 (t, J = 7.4 Hz, 2H), 2.10 (s, 1H). To N-(4-iodo-2(hydroxymethyl)phenyl)-3-(furan-2-yl)propanamide (0.90 g) in DCM (60 mL) was
added PCC (3.15 g, 14.6 mmol). The reaction mixture was left stirring for 8 hours,
filtered through a layer of silica gel using EtOAc, concentrated, and the mixture was
subjected to flash chromatography yielding 0.37 g (34%) of the product over two steps.
1

H NMR (500 MHz, CDCl3) δ 11.08 (s, 1H), 9.85 (s, 1H), 8.58 (d, J = 8.9 Hz, 1H), 7.97

(d, J = 2.2 Hz, 1H), 7.89 (dd, J = 8.9, 2.2 Hz, 1H), 7.33 (dd, J = 1.8, 0.9 Hz, 1H), 6.29
(dd, J = 3.2, 1.9 Hz, 1H), 6.09 (m, 1H), 3.11 (m, 2H), 2.83 (m, 2H).

13

C NMR (126 MHz,

CDCl3) δ 194.2, 171.2, 153.8, 144.6, 144.1, 141.4, 140.4, 123.3, 122.0, 110.2, 105.6,
84.7, 36.6, 23.6. HRMS (ESI) calcd for C14H13INO3+ (MH+) 369.9935, found 369.9945.
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N-(2-acetyl-4-bromophenyl)-3-(furan-2-yl)propanamide
(3.12): General procedure FC was followed using 2furanpropanoyl chloride (2 eq, 0.72 g, 2.8 mmol), 1-(2-amino5-bromophenyl)ethanone (1 eq, 0.30 g, 1.4 mmol) and
anhydrous pyridine (1.5 eq, 0.17 mL, 2.1 mmol). The concentration yielded 0.45 g
(93%) of the product. 1H NMR (500 MHz, CDCl3) δ 11.66 (s, 1H), 8.73 (d, J = 9.0 Hz,
1H), 8.01 (d, J = 2.4 Hz, 1H), 7.66 (dd, J = 9.1, 2.4 Hz, 1H), 7.33 (dd, J = 1.9, 0.8 Hz,
1H), 6.29 (dd, J = 3.2, 1.9 Hz, 1H), 6.08 (m, 1H), 3.10 (m, 2H), 2.81 (m, 2H), 2.68 (s,
3H).

13

C NMR (126 MHz, CDCl3) δ 201.6, 171.1, 154.0, 141.3, 139.9, 137.8, 134.0,

123.2, 122.6, 114.6, 110.2, 105.5, 36.7, 28.6, 23.7. HRMS (ESI) calcd for C15H15BrNO3+
(MH+) 336.0230, found 336.0235.

N-(4-bromo-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)-3(furan-2-yl)propanamide (3.13): General procedure FC was
followed using 2-furanpropanoyl chloride (3.8 mmol), 8amino-5-bromo-3,4-dihydronaphthalen-1(2H)-one (0.48 g,
2.0 mmol) and dry pyridine (0.18 mL, 2.2 mmol). Purification by flash chromatography
yielded 0.38 g of the title compound (50%). 1H NMR (500 MHz, CDCl3) δ 12.23 (s, 1H),
8.61 (d, J = 9.1 Hz, 1H), 7.72 (d, J = 9.1 Hz, 1H), 7.33 (dd, J = 1.9, 0.8 Hz, 1H), 6.29
(dd, J = 3.2, 1.9 Hz, 1H), 6.08 (m, 1H), 3.10 (m, 2H), 3.06 (t, J = 6.2 Hz, 2H), 2.82 (m,
2H), 2.72 (m, 2H), 2.14 (m, 2H).

13

C NMR (126 MHz, CDCl3) δ 203.0, 171.2, 154.1,
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144.1, 141.3, 141.3, 138.8, 120.0, 119.7, 117.5, 110.2, 105.4, 40.1, 36.8, 31.4, 23.7, 21.7.
HRMS (ESI) calcd for C17H17BrNO3+ (MH+) 362.0386, found 362.0382.

N-(2-(4-bromo-2-formylphenylamino)-2-oxoethyl)-N(furan-2-ylmethyl)pivalamide (S11): General procedure BB
was followed using 4-bromo-2((trimethylsilyl)methyl)aniline (2.28 g, 8.32 mmol), DIPEA
(1.65 mL, 9.98 mmol) and bromoacetyl bromide (0.86 mL, 9.9 mmol). The workup
yielded 2-bromo-N-(4-bromo-2-(hydroxymethyl)phenyl)acetamide (3.07 g) which
was used without further purification. 1H NMR (500 MHz, CDCl3) δ 9.51 (s, 1H), 8.02
(d, J = 8.7 Hz, 1H), 7.50 (dd, J = 8.7, 2.4 Hz, 1H), 7.39 (d, J = 2.3 Hz, 1H), 4.75 (s, 2H),
4.06 (s, 2H). To N-(4-bromo-2-(hydroxymethyl)phenyl)acetamide (1.20 g) and
DIPEA (0.71 mL, 4.1 mmol) in DCM (30 mL) was added furfuryl amine (0.49 mL, 5.5
mmol). The mixture was allowed to stir overnight, quenched with water (100 mL), the
organic phase was separated, and the aqueous layer was extracted with DCM (3 x 100
mL). The combined organic fractions were washed with brine, dried over Na2SO4,
filtered, and concentrated yielding N-(4-bromo-2-(hydroxymethyl)phenyl)-2-(furan-2ylmethylamino)acetamide (1.53 g crude) which was used without further purification.
1

H NMR (500 MHz, CDCl3) δ 10.07 (s, 1H), 8.02 (d, J = 8.6 Hz, 1H), 7.45 (dd, J = 8.6,

2.4 Hz, 1H), 7.41 (d, J = 2.4 Hz, 1H), 7.39 (dd, J = 1.9, 0.8 Hz, 1H), 6.36 – 6.34 (m, 1H),
6.28 – 6.27 (m, 1H), 4.66 (s, 2H), 3.88 (s, 2H), 3.47 (s, 2H). To N-(4-bromo-2(hydroxymethyl)phenyl)-2-(furan-2-ylmethylamino)acetamide (1.08 g) and DIPEA
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(0.30 mL, 1.8 mmol) in DCM (100 mL) was added pivaloyl chloride (0.19 mL, 1.5
mmol). The mixture was allowed to stir overnight, quenched with water (100 mL), the
organic phase was separated, and the aqueous layer was extracted with DCM (3 x 100
mL). The combined organic fractions were dried over Na2SO4, filtered, and
concentrated. Purification by flash chromatography yielded 0.40 g (29%) of the product
over three steps. 1H NMR (500 MHz, CDCl3) δ 9.11 (s, 1H), 7.88 (d, J = 8.7 Hz, 1H),
7.39 (dd, J = 8.7, 2.4 Hz, 1H), 7.37 (dd, J = 1.8, 0.8 Hz, 1H), 7.32 (d, J = 2.4 Hz, 1H),
6.36 (dd, J = 3.2, 1.9 Hz, 1H), 6.32 (m, 1H), 4.79 (s, 2H), 4.60 (d, J = 4.8 Hz, 2H), 4.10
(s, 2H), 3.48 (s, 1H), 1.39 (s, 9H ).

N-(2-(4-bromo-2-formylphenylamino)-2-oxoethyl)-N-(furan2-ylmethyl)pivalamide (3.14): To a stirred solution of N-(2(4-bromo-2-formylphenylamino)-2-oxoethyl)-N-(furan-2ylmethyl)pivalamide (0.35 g, 0.83 mmol) in 40 mL of DCM
was added MnO2 (1.02 g, 11.7 mmol). After stirring for 24 hours the solution was
filtered through Celite® and concentrated yielding the product (0.28 g, 0.67 mmol, 23%
over four steps). 1H NMR (500 MHz, CDCl3) δ 11.19 (s, 1H), 9.85 (d, J = 0.7 Hz, 1H),
8.68 (d, J = 9.0 Hz, 1H), 7.79 (d, J = 2.4 Hz, 1H), 7.70 (dd, J = 9.0, 2.4 Hz, 1H), 7.34
(dd, J = 1.8, 0.9 Hz, 1H), 6.33 (dd, J = 3.3, 1.8 Hz, 1H), 6.31 (dd, J = 3.3, 0.9 Hz, 1H),
4.87 (s, 2H), 4.17 (s, 2H), 1.45 (s, 9H). HRMS (ESI) calcd for C19H22BrN2O4+ (MH+)
421.0757, found 421.0757.
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N-(2-(4-bromo-8-oxo-5,6,7,8-tetrahydronaphthalen-1ylamino)-2-oxoethyl)-N-(furan-2-ylmethyl)pivalamide (3.15):
General procedure BB was followed using 8-amino-5-bromo3,4-dihydronaphthalen-1(2H)-one (1.15 g, 4.79 mmol), pyridine
(0.77 mL, 9.56 mmol), bromoacetyl bromide (0.50 mL, 5.7
mmol). The workup yielded 2-bromo-N-(4-bromo-8-oxo-5,6,7,8tetrahydronaphthalen-1-yl)acetamide (1.67 g) which was used without further
purification. 1H NMR (500 MHz, CDCl3) δ 12.80 (s, 1H), 8.56 (d, J = 9.1 Hz, 1H), 7.76
(d, J = 9.1 Hz, 1H), 4.04 (s, 2H), 3.08 (t, J = 6.2 Hz, 2H), 2.76 (m, 2H), 2.16 (m, 2H). To
2-bromo-N-(4-bromo-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide (1.67 g)
and DIPEA (1.21 mL, 6.95 mmol) in DCM (75 mL) was added furfuryl amine (0.61 mL,
0.67 mmol). The mixture was allowed to stir overnight, quenched with water (50 mL),
the organic phase was separated, and the aqueous layer was extracted with DCM (3 x 100
mL). The combined organic fractions were washed with brine, dried over Na2SO4,
filtered, and concentrated yielding N-(4-bromo-8-oxo-5,6,7,8-tetrahydronaphthalen-1yl)-2-(furan-2-ylmethylamino)acetamide (1.60 g) which was used without further
purification 1H NMR (500 MHz, CDCl3) δ 12.85 (s, 1H), 8.66 (d, J = 9.1 Hz, 1H), 7.73
(d, J = 9.1 Hz, 1H), 7.38 (dd, J = 1.9, 0.9 Hz, 1H), 6.34 (dd, J = 3.2, 1.7 Hz, 1H), 6.29
(dd, J = 3.2, 0.8 Hz, 1H), 3.92 (s, 2H), 3.48 (s, 2H), 3.07 (t, J = 6.2 Hz, 2H), 2.73 (m,
2H), 2.14 (m, 2H). To N-(4-bromo-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)-2(furan-2-ylmethylamino)acetamide (1.60 g) and DIPEA (0.96 mL, 5.5 mmol) in DCM
(75 mL) was added pivaloyl chloride (0.68 mL, 5.5 mmol). The mixture was allowed to
62

stir overnight, quenched with water (75 mL), the organic phase was separated, and the
aqueous layer was extracted with DCM (3 x 100 mL). The combined organic fractions
were dried over Na2SO4, filtered, and concentrated. Purification by flash
chromatography yielded 0.43 g (19%) of the product over three steps. 1H NMR (500
MHz, CDCl3) δ 12.35 (s, 1H), 8.57 (d, J = 9.1 Hz, 1H), 7.71 (d, J = 9.1 Hz, 1H), 7.36
(dd, J = 1.8, 0.9 Hz, 1H), 6.34 (dd, J = 3.2, 1.8 Hz, 1H), 6.29 (dd, J = 3.3, 0.9 Hz, 1H),
4.85 (s, 2H), 4.18 (s, 2H), 3.05 (t, J = 6.2 Hz, 2H), 2.70 (m, 2H), 2.12 (m, 2H), 1.42 (s,
9H).

13

C NMR (126 MHz, CDCl3) δ 202.6, 178.2, 168.5, 150.1, 144.1, 142.6, 140.8,

138.7, 120.2, 119.9, 117.9, 110.4, 109.0, 52.0, 46.2, 40.0, 39.2, 31.4, 28.6, 21.7. HRMS
(ESI) calcd for C22H26BrN2O4+ (MH+) 461.1070, found 461.1073.

N-benzyl-N-(2-(4-bromo-8-oxo-5,6,7,8tetrahydronaphthalen-1-ylamino)-2-oxoethyl)furan-2carboxamide (3.16): General procedure BB was followed
using 8-amino-5-bromo-3,4-dihydronaphthalen-1(2H)-one
(0.42 g, 1.7 mmol), DIPEA (0.36 mL, 2.1 mmol) and
bromoacetyl bromide (0.18 mL, 2.1 mmol). The workup yielded 2-bromo-N-(4-bromo8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide (0.70 g) which was used without
further purification. 1H NMR (500 MHz, CDCl3) δ 12.80 (s, 1H), 8.56 (d, J = 9.1 Hz,
1H), 7.76 (d, J = 9.1 Hz, 1H), 4.04 (s, 2H), 3.08 (t, J = 6.2 Hz, 2H), 2.76 (m, 2H), 2.16
(m, 2H). To 2-bromo-N-(4-bromo-8-oxo-5,6,7,8-tetrahydronaphthalen-1yl)acetamide (0.70 g) and DIPEA (0.34 mL, 2.0 mmol) in DCM (40 mL) was added
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benzyl amine (0.29 mL, 2.7 mmol). The mixture was allowed to stir overnight, quenched
with water (50 mL), the organic phase was separated, and the aqueous layer was
extracted with DCM (3 x 100 mL). The combined organic fractions were dried over
Na2SO4, filtered, and concentrated yielding 2-(benzylamino)-N-(4-bromo-8-oxo-5,6,7,8tetrahydronaphthalen-1-yl)acetamide (0.88 g) 1H NMR (500 MHz, CDCl3) δ 12.92 (s,
1H), 8.67 (d, J = 9.1, 0.7 Hz, 1H), 7.72 (d, J = 9.1 Hz, 1H), 7.47 (m, 2H), 7.37 (m, 3H),
3.93 (s, 2H), 3.50 (s, 2H), 3.07 (t, J = 6.2 Hz, 2H), 2.75 (m, 2H), 2.15 (m, 2H). To 2(benzylamino)-N-(4-bromo-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide (0.88
g) and DIPEA (0.44 mL, 2.5 mmol) in DCM (45 mL) was added 2-furoyl chloride (0.27
mL, 2.7 mmol). The mixture was allowed to stir overnight, quenched with water (50
mL), the organic phase was separated, and the aqueous layer was extracted with DCM (3
x 100 mL). The combined organic fractions were dried over Na2SO4, filtered, and
concentrated. Purification by flash chromatography yielded 0.32 g (39%) of the product
over three steps. 1H NMR (500 MHz, CDCl3) 1H NMR (500 MHz, CDCl3) δ 12.68 (m,
1H), 8.63 (d, J = 8.8 Hz, 1H), 7.74 (d, J = 9.1 Hz, 1H), 7.50 (m, 1H), 7.36 (m, 5H), 7.21
(m, 1H), 6.51 (m, 1H), 5.04 (m, 2H), 4.28 (m, 2H), 3.05 (m, 2H), 2.69 (m, 2H), 2.12 (m,
2H).

13

C NMR (126 MHz, CDCl3) δ 202.8, 163.5, 144.6, 144.3, 140.7, 138.8, 136.5,

136.2, 135.0, 129.1, 128.9, 128.9, 128.4, 127.8, 127.8, 120.3, 119.7, 118.1, 111.6, 52.2,
46.6, 40.0, 31.4, 21.7. HRMS (ESI) calcd for C24H22BrN2O4+ (MH+) 481.0757, found
481.0758.
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N-(2-formyl-4-(pyridin-3-yl)phenyl)-3-(furan-2yl)propanamide (3.3b): General procedure for Suzuki
coupling SPy with pyridine boronic acid using
pyridine-3-boronic acid (0.39 g, 3.2 mmol), Pd2(dba)3 (0.035 g, 0.038 mmol), PCy3
(0.027 g, 0.096 mmol), and N-(4-bromo-2-(hydroxymethyl)phenyl)-3-(furan-2yl)propanamide (0.61 g, 1.9 mmol), dioxane (5.0 mL), and aqueous K3PO4 (5.0 mmol,
3.9 mL of a 1.27 M solution) was followed. The crude 3-(furan-2-yl)-N-(2(hydroxymethyl)-4-(pyridin-3-yl)phenyl)propanamide (0.60 g) was used without further
purification 1H NMR (500 MHz, CDCl3) δ 8.81 (s, 1H), 8.63 (s, 1H), 8.56 (dd, J = 4.8,
1.1 Hz, 1H), 8.25 (d, J = 8.4 Hz, 1H), 7.84 (ddd, J = 7.9, 2.4, 1.6 Hz, 1H), 7.52 (dd, J =
8.4, 2.2 Hz, 1H), 7.37 (m, 3H), 6.33 (dd, J = 3.2, 1.9 Hz, 1H), 6.13 (dd, J = 3.1, 0.6 Hz,
1H), 4.75 (s, 2H), 3.14 (t, J = 7.5 Hz, 2H), 2.81 (t, J = 7.5 Hz, 2H), 1.41 (s, 1H). To a
stirred solution of 3-(furan-2-yl)-N-(2-(hydroxymethyl)-4-(pyridin-3yl)phenyl)propanamide (0.60 g, 1.9 mmol) in DCM (45 mL) was added MnO2 (2.28 g,
26.2 mmol). After 24 hours, the solution was filtered through Celite®, concentrated, and
purified by flash chromatography yielding 0.31g (51%) of the product over two steps. 1H
NMR (500 MHz, CDCl3) δ 11.22 (s, 1H), 10.05 (s, 1H), 8.92 (d, J = 8.7 Hz, 1H), 8.90
(dd, J = 2.4, 0.9 Hz, 1H), 8.66 (dd, J = 4.8, 1.6 Hz, 1H), 7.91 (m, 2H), 7.86 (dd, J = 8.7,
2.3 Hz, 1H), 7.43 (ddd, J = 7.9, 4.8, 0.9 Hz, 1H), 7.35 (dd, J = 1.9, 0.9 Hz, 1H), 6.31 (dd,
J = 3.2, 1.9 Hz, 1H), 6.11 (m, 1H), 3.14 (m, 2H), 2.88 (m, 2H).

13

C NMR (126 MHz,

CDCl3) δ 195.3, 171.3, 153.9, 149.0, 147.9, 141.3, 140.6, 134.6, 134.5, 134.2, 133.9,
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132.6, 123.7, 122.0, 120.8, 110.2, 105.6, 36.6, 23.6. HRMS (ESI) calcd for C19H17N2O3+
(MH+) 321.1234, found 321.1241.

Irradiation and Suzuki coupling of the photoproducts

General Scheme and Procedure for the Irradiation and Subsequent Coupling of BromoSubstituted Aromatic Compounds with Pyridine-3-Boronic Acid

General procedure for irradiation (I): Solutions with ca. 6.0 mM of the
photoprecursors 3.3a-3.3e, 3.9, 3.12-3.16 in 5% aq. acetonitrile were degassed by
sparging with N2 and irradiated in Pyrex or borosilicate glass reaction vessels in a
Rayonet reactor equipped with RPR-3500 UV lamps (broadband 300-400 nm UV source
with peak emission at 350 nm) until the reaction was complete, as determined by 1H
NMR. The solution was concentrated and the cycloaddition products were used without
further purification.
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General procedure for Suzuki coupling with pyridine-3-boronic acid (SPy):
Aqueous K3PO4 (1.70 mmol, 1.33 mL of a 1.27 M solution), degassed by sparging with
N2 for 30 min, was added to the reaction mixture containing pyridine-3-boronic acid (1.1
mmol, 1.1 eq), Pd2(dba)3 (0.01 mmol, 0.9mol%), PCy3 (0.024 mmol, 2.2 mol%), and the
heteroaryl bromide (1.0 mmol, 1.0 eq) in dioxane (2.67 mL) under nitrogen atmosphere.
The mixture was refluxed for 36 hours with vigorous stirring, cooled to room
temperature, filtered through a layer of silica gel using extra allotments of EtOAc,
concentrated, diluted with water (40 mL) and extracted with EtOAc (3 x 75 mL). The
combined organic fractions were dried over Na2SO4, filtered, concentrated, and the
product(s) were purified using flash chromatography yielding the isolated coupling
products.

General procedure for Suzuki coupling with phenylboronic acid (SPh): The
heteroaryl halide (0.94 mmol, 1eq) and Pd(PPh3)4 (5.3 mol%, 0.050 mmol), were
suspended in dimethoxyethane (4 mL) the mixture was allowed to stir under nitrogen
atmosphere for 10 min. Phenylboronic acid (1.17 eq, 1.1 mmol) followed by aq. Na2CO3
(1.06 mL, 2 M solution, 2.12 mmol) were added to the mixture, and the resulting solution
was refluxed under nitrogen atmosphere for 24 hours. The mixture was allowed to cool
to room temperature, extracted with Et2O (6 x 40 mL), and the combined organic
fractions were washed with water, dried over Na2SO4, concentrated, and subjected to
flash chromatography.
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General procedure for Suzuki coupling with thiophene-2- and furan-2boronic acids (STF): To a stirred mixture of the heteroaryl iodide (0.20 g, 0.54 mmol)
and Pd(PPh3)4 (5.2-5.8 mol%, 0.032 g, 0.028 mmol) in DME (16 mL) was added
thiophene-2- or furan-2-boronic acid (0.077 g, 0.60 mmol). The mixture was placed
under nitrogen atmosphere, and NaHCO3 (0.095 g, 1.1 mmol) in H2O (16 mL) was
added. The reaction mixture was heated under reflux with vigorous stirring for 12 hours.
Subsequently, the organic solvent was removed under reduced pressure, an extraction
was performed on the remaining aqueous layer using EtOAc (5 x 25 mL), the combined
organic fractions were dried using MgSO4, filtered, concentrated, and subjected to flash
chromatography.

8-Hydroxy-5-phenyl-12-oxa-1azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10-tetraen-16one (3.4f): General procedure I was followed. From N-(4bromo-2-formylphenyl)-3-(furan-2-yl)propanamide (3.3a)
(1.0 g, 3.1 mmol) a mixture 5-bromo-8-hydroxy-12-oxa-1azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10-tetraen-16-one (3.4a) and 5-bromo-2hydroxy-16-oxa-9-azatetracyclo[11.2.1.03,8.05,9]hexadeca-3,5,7,14-tetraen-10-one
(3.5a) in the ratio of 1:1 was formed, which was introduced into Suzuki coupling
following the general procedure SPh. From 0.3 g of that mixture (0.94 mmol),
phenylboronic acid (0.13 g, 1.1 mmol), Pd(PPh3)4 (0.058 g, 0.05 mmol) Na2CO3 (1.06
mL of a 2 M solution, 2.12 mmol) 0.089 g (30%) of the title compound and 0.13 g (44%)
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of 2-hydroxy-5-phenyl-16-oxa-9-azatetracyclo[11.2.1.03,8.05,9]hexadeca-3,5,7,14tetraen-10-one (3.5f) were isolated. 1H NMR (500 MHz, CDCl3) δ 7.98 (d, J = 8.3 Hz,
1H), 7.64 (dd, J = 8.3, 2.1 Hz, 1H), 7.59 (m, 2H), 7.46 (m, 3H), 7.38 (m, 1H), 6.27 (t, J =
2.8 Hz, 1H), 4.84 (d, J = 2.1 Hz, 1H), 4.70 (dd, J = 3.1, 2.2 Hz, 1H), 3.89 (q, J = 2.3 Hz,
1H), 2.86 (m, 1H), 2.59 (m, 1H), 2.47 (m, 2H), 2.19(s, 1H).

13

C NMR (126 MHz,

CDCl3) δ 173.4, 146.7, 140.1, 138.8, 133.3, 131.3, 128.9, 128.2, 127.5, 127.4, 126.9,
123.5, 101.4, 99.4, 70.5, 56.1, 35.2, 29.8. HRMS (ESI) calcd for C20H18NO3+ (MH+)
320.1281, found 320.1281.

2-Hydroxy-5-phenyl-16-oxa-9azatetracyclo[11.2.1.03,8.05,9]hexadeca-3,5,7,14-tetraen-10-one
(3.5f): General procedure I was followed. From N-(4-bromo-2formylphenyl)-3-(furan-2-yl)propanamide (3.3a) (1.0 g, 3.1 mmol) a 5-bromo-8hydroxy-12-oxa-1-azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10-tetraen-16-one
(4a) and 5-bromo-2-hydroxy-16-oxa-9-azatetracyclo[11.2.1.03,8.05,9]hexadeca3,5,7,14-tetraen-10-one (3.5a) in the ratio of 1:1 was formed, which was introduced into
Suzuki coupling following the general procedure SPh From 0.3 g of the mixture (0.94
mmol), phenylboronic acid (0.13 g, 1.1 mmol), Pd(PPh3)4 (0.058g, 0.05 mmol) Na2CO3
(1.06 mL of a 2 M solution, 2.12 mmol) 0.13 g (44%) of the title compound and 0.089 g
(30%) of 8-hydroxy-5-phenyl-12-oxa-1-azatetracyclo[11.3.0.02,7.09,13]hexadeca2,4,6,10-tetraen-16-one (3.4f) was isolated. 1H NMR (500 MHz, CDCl3) δ 7.60 (m, 4H),
7.54 (m, 1H), 7.45 (m, 2H), 7.38 (m, 1H), 6.36 (dd, J = 5.9, 1.9 Hz, 1H), 5.70 (dd, J =
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5.8, 1.1 Hz, 1H), 5.09 (m, 1H), 4.75 (d, J = 7.0 Hz, 1H), 3.15 (s, 1H), 2.89 (m, 1H), 2.65
(m, 1H), 2.57 (dt, J=13.8, 9.8, 1H), 2.48 (ddd, J=13.9, 9.5, 1.7, 1H) .

13

C NMR (126

MHz, CDCl3) δ 173.2, 139.9, 139.5, 134.8, 133.5, 131.6, 131.2, 129.3, 128.8, 128.0,
127.5, 127.2, 127.0, 103.6, 83.7, 79.5, 30.0, 28.9. HRMS (ESI) calcd for C20H18NO3+
(MH+) 320.1281, found 320.1283.

8-Hydroxy-5-pyridin-3-yl-12-oxa-1azatetracyclo[11.3.0.02,7.09,13] hexadeca-2,4,6,10-tetraen-16one (3.4b): Pathway A: 0.25 g (0.78 mmol) of N-(2-formyl-4(pyridin-3-yl)phenyl)-3-(furan-2-yl)propanamide (3.3b) was irradiated following the
general procedure I. Flash chromatography resulted in an isolated yield of 0.12 g (47%)
of the title compound and 0.10g (40%) of 2-Hydroxy-5-pyridin-2-yl-16-oxa-9azatetracyclo[11.2.1.03,8.05,9]hexadeca-3,5,7,14-tetraen-10-one (3.5b).
Pathway B: 0.34 g (1.1 mmol) of N-(4-bromo-2-formylphenyl)-3-(furan-2yl)propanamide (3.3a) was irradiated following general procedure I yielding a mixture
of a 5-bromo-8-hydroxy-12-oxa-1-azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10tetraen-16-one (3.4a) and 5-bromo-2-hydroxy-16-oxa-9azatetracyclo[11.2.1.03,8.05,9]hexadeca-3,5,7,14-tetraen-10-one (3.5a) in the ratio of
1:1. 0.34 g of the mixture was then introduced into Suzuki coupling following general
procedure SPy using pyridine-3-boronic acid (0.23 g, 1.9 mmol), Pd2(dba)3 (0.021 g,
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0.023 mmol), PCy3 (0.016 g, 0.057 mmol), dioxane (3.1 mL), and aqueous K3PO4 (2.86
mmol, 2.3 mL of a 1.27 M solution) resulting in an isolated yield of 0.024 g, (6.8%) of
the title compound and 0.10 g (28%) of 2-Hydroxy-5-pyridin-2-yl-16-oxa-9azatetracyclo[11.2.1.03,8.05,9]hexadeca-3,5,7,14-tetraen-10-one (3.5b) 1H NMR (500
MHz, CDCl3) δ 8.64 (d, J = 2.4 Hz, 1H), 8.56 (dd, J = 4.8, 1.6 Hz, 1H), 8.05 (d, J = 8.3
Hz, 1H), 7.83 (ddd, J = 8.0, 2.4, 1.6 Hz, 1H), 7.57 (dd, J = 8.3, 2.1 Hz, 1H), 7.41 (d, J =
2.1 Hz, 1H), 7.36 (ddd, J = 8.0, 4.8, 0.9 Hz, 1H), 6.29 (t, J = 2.8 Hz, 1H), 4.88 (d, J = 2.2
Hz, 1H), 4.71 (dd, J = 3.1, 2.3 Hz, 1H), 3.93 (q, J = 2.3 Hz, 1H), 2.90 (ddd, J = 16.1,
10.3, 8.2 Hz, 1H), 2.56 (m, 3H), 1.64 (s, 1H).

13

C NMR (126 MHz, CDCl3) δ 173.3,

148.4, 148.0, 146.8, 135.7, 135.1,134.4, 134.2, 131.8, 128.2, 127.4, 123.8, 123.6, 101.4,
99.4, 70.3, 56.1, 35.2, 29.8 HRMS (ESI) calcd for C19H17N2O3+ (MH+) 321.1234, found
321.1241.

2-Hydroxy-5-pyridin-2-yl-16-oxa-9azatetracyclo[11.2.1.03,8.05,9]hexadeca-3,5,7,14-tetraen-10-one
(3.5b): Pathway A: 0.25 g (0.78 mmol) of N-(2-formyl-4(pyridin-3-yl)phenyl)-3-(furan-2-yl)propanamide was irradiated
following the general procedure I. Flash chromatography resulted in an isolated yield of
0.12 g (47%) of 8-hydroxy-5-(pyridin-3-yl)-12-oxa-1azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10-tetraen-16-one (3.4b) and 0.10 g
(40%) of the title compound.
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Pathway B: 0.34 g (1.1 mmol) of N-(4-Bromo-2-formylphenyl)-3-(furan-2yl)propanamide (3.3a) was irradiated following general procedure for irradiation
yielding a mixture of a 5-bromo-8-hydroxy-12-oxa-1azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10-tetraen-16-one (4a) and 5-bromo-2hydroxy-16-oxa-9-azatetracyclo[11.2.1.03,8.05,9]hexadeca-3,5,7,14-tetraen-10-one
(3.5a) in the ratio of 1:1. 0.34 g of the mixture was then subjected to general procedure
SPy using pyridine-3-boronic acid (0.23 g, 1.9 mmol), Pd2(dba)3 (0.021 g, 0.023 mmol),
PCy3 (0.016 g, 0.057 mmol), dioxane (3.1 mL), and aqueous K3PO4 (2.86 mmol, 2.3 mL ,
1.27 M solution) resulting in an isolated yield of 0.024 g (6.8%) of 8-hydroxy-5-pyridin3-yl-12-oxa-1-azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10-tetraen-16-one (3.4b)
and 0.10 g (28%) of the title compound. 1H NMR (500 MHz, CDCl3) δ 8.83 (d, J = 2.1
Hz, 1H), 8.61 (dd, J = 4.8, 1.6 Hz, 1H), 7.88 (dt, J = 8.0, 1.9 Hz, 1H), 7.65 (d, J = 8.3 Hz,
1H), 7.58 (dd, J = 8.4, 2.2 Hz, 1H), 7.53 (d, J = 2.2 Hz, 1H), 7.39 (ddd, J = 7.9, 4.8, 0.9
Hz, 1H), 6.38 (dd, J = 5.8, 1.8 Hz, 1H), 5.71 (dd, J = 5.8, 1.2 Hz, 1H), 5.10 (m, 1H), 4.76
(d, J = 3.3 Hz, 1H), 2.91 (dt, J = 17.2, 9.7 Hz, 1H), 2.67 (ddd, J=17.2, 9.8, 1.8, 1H), 2.58
(dt, J=13.8, 9.8, 1H), 2.50 (ddd, J=13.8, 9.5, 1.8, 1H). 13C NMR (126 MHz, CDCl3) δ
173.3, 148.7, 148.1, 136.0, 135.4, 134.8, 134.2, 133.9, 132.5, 131.2, 129.3, 128.4, 127.2,
123.6, 103.6, 83.6, 79.4, 30.0, 28.9. HRMS (ESI) calcd for C19H17N2O3+ (MH+)
321.1234, found 321.1241.
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8-Hydroxy-6-(pyridin-3-yl)-12-oxa-1azatetracyclo[11.3.0.02,7.09,13] hexadeca-2,4,6,10-tetraen-16one (3.17b): General procedure I was followed using 0.25 g
(0.78 mmol) of N-(5-bromo-2-formylphenyl)-3-(furan-2yl)propanamide (3.9) yielding a mixture of 6-bromo-8-hydroxy-12-oxa-1azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10-tetraen-16-one (3.17a) and 6-bromo2-hydroxy-16-oxa-9-azatetracyclo[11.2.1.03,8.05,9]hexadeca-3,5,7,14-tetraen-10-one
(3.18a) in the ratio of 1:0.8. 0.25 g of the mixture was then subjected to general
procedure for Suzuki coupling SPy using pyridine-3-boronic acid (0.14 g, 1.1 mmol),
Pd2(dba)3 (0.014 g, 0.015 mmol), PCy3 (0.012 g, 0.043 mmol), dioxane (2.25 mL), and
aqueous K3PO4 (0.73 mmol, 0.97 mL of a 1.27 M solution) resulting in an isolated yield
of 0.072 g (28%) of the title compound and 0.059 g (23%) of 2-hydroxy-6-(pyridin-3yl)-16-oxa-9-azatetracyclo[11.2.1.03,8.05,9]hexadeca-3,5,7,14-tetraen-10-one (3.18b) 1H
NMR (500 MHz, CDCl3) δ 8.53 (d, J = 4.8 Hz, 1H), 8.41 (s, 1H), 8.12 (d, J = 1.7 Hz,
1H), 7.89 (ddd, J = 7.9, 2.4, 1.6 Hz, 1H), 7.33 (m, 2H), 6.28 (t, J = 2.8 Hz, 1H), 4.86 (d, J
= 2.2 Hz, 1H), 4.71 (dd, J = 3.0, 2.2 Hz, 1H), 3.93 (q, J = 2.4 Hz, 1H), 2.88 (m, 1H), 2.56
(m, 4H), 1.64 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 173.3, 148.3, 148.0, 146.7, 139.1,
135.0, 134.7, 131.0, 129.5, 124.3, 123.6, 121.9, 101.5, 99.5, 69.8, 56.2, 35.2, 29.9.
HRMS (ESI) calcd for C19H17N2O3+ (MH+) 321.1234, found 321.1237.
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2-Hydroxy-6-(pyridin-3-yl)-16-oxa-9azatetracyclo[11.2.1.03,8.05,9]hexadeca-3,5,7,14-tetraen-10-one
(3.18b): General procedure I was followed using 0.25 g (0.78
mmol) of N-(5-bromo-2-formylphenyl)-3-(furan-2yl)propanamide (3.9) yielding a mixture of 6-bromo-8-hydroxy-12-oxa-1azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10-tetraen-16-one (3.17a) and 6-bromo2-hydroxy-16-oxa-9-azatetracyclo[11.2.1.03,8.05,9]hexadeca-3,5,7,14-tetraen-10-one
(3.18a) in the ratio of 1:0.8. 0.25 g of the mixture was then subjected to general
procedure for Suzuki coupling SPy using pyridine-3-boronic acid (0.14 g, 1.1 mmol),
Pd2(dba)3 (0.014 g, 0.015 mmol), PCy3 (0.012 g, 0.043 mmol), dioxane (2.25 mL), and
aqueous K3PO4 (0.73 mmol, 0.97 mL of a 1.27 M solution) resulting in an isolated yield
of 0.072 g (28%) of 8-hydroxy-6-(pyridin-3-yl)-12-oxa-1azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10-tetraen-16-one (3.17b) and 0.059 g
(23%) of the title compound. 1H NMR (500 MHz, CDCl3) δ 8.84 (s, 1H), 8.61 (s, 1H),
7.91 (dt, J = 8.0, 2.0 Hz, 1H), 7.76 (d, J = 1.8 Hz, 1H), 7.43 (m, 2H), 7.38 (t, J = 7.5, 4.8
Hz, 1H), 6.37 (dd, J = 5.9, 1.9 Hz, 1H), 5.71 (dd, J = 5.9, 1.2 Hz, 1H), 5.08 (m, 1H), 4.73
(s, 1H), 3.17 (s, 1H), 2.94 (m, 1H), 2.68 (ddd, J = 17.3, 9.8, 1.8 Hz, 1H), 2.58 (dt, J=13.9,
9.8, 1H), 2.50 (ddd, J=13.9, 9.5, 1.8, 1H). 13C NMR (126 MHz, CDCl3) δ 173.1, 148.8,
148.2, 138.2, 134.8, 134.5, 133.4, 133.2, 132.8, 129.3, 126.4, 125.1, 123.6, 103.7, 83.6,
79.0, 30.1, 28.9. HRMS (ESI) calcd for C19H17N2O3+ (MH+) 321.1234, found 321.1240.
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8-Hydroxy-8-methyl-5-(pyridin-3-yl)-12-oxa-1azatetracyclo [11.3.0.02,7.09,13]hexadeca-2,4,6,10-tetraen-16one (3.19b): General procedure I was followed using 0.50 g
(1.5 mmol) of N-(2-acetyl-4-bromophenyl)-3-(furan-2yl)propanamide (3.10) yielding 0.50 g of a mixture of 5-bromo-8-hydroxy-8-methyl12-oxa-1-azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10-tetraen-16-one (3.19a) and
5-bromo-2-hydroxy-2-methyl-16-oxa-9-azatetracyclo[11.2.1.03,8.05,9]hexadeca3,5,7,14-tetraen-10-one (3.20a) in the ratio of 1:1. 0.25 g of the mixture was then
subjected to general procedure for Suzuki coupling SPy using pyridine-3-boronic acid
(0.14 g, 1.1 mmol), Pd2(dba)3 (0.014 g, 0.015 mmol), PCy3 (0.012 g, 0.043 mmol),
dioxane (2.25 mL), and aqueous K3PO4 (0.73 mmol, 0.97 mL of a 1.27 M solution)
resulting in an isolated yield of 0.071 g, (28%) of the title compound and 0.072 g (30%)
of 2-Hydroxy-2-methyl-3,4-(4’-pyridin-3-yl)benzo-12-oxa-5-azatricyclo[7.2.1.05,9]dodec-3,10-dien-6-one (3.20b). 1H NMR (500 MHz, CDCl3) δ 8.43
(dd, J = 4.8, 1.7 Hz, 1H), 8.22 (d, J = 2.4 Hz, 1H), 7.94 (d, J = 8.2 Hz, 1H), 7.73 (ddd, J
= 7.9, 2.4, 1.6 Hz, 1H), 7.43 (dd, J = 8.2, 2.0 Hz, 1H), 7.38 (d, J = 2.1 Hz, 1H), 7.28 (dd,
J = 7.8, 4.8 Hz, 1H), 6.25 (t, J = 2.8 Hz, 1H), 4.65 (dd, J = 3.1, 2.2 Hz, 1H), 4.18 (s, 1H),
3.74 (t, J = 2.4 Hz, 1H), 2.85 (m, 1H), 2.52 (m, 3H), 1.79 (s, 3H).

13

C NMR (126 MHz,

CDCl3) δ 173.3, 147.9, 147.8, 146.9, 136.1, 134.9, 134.5, 134.3, 134.3, 127.4, 124.1,
123.7, 123.5, 101.6, 99.1, 70.5, 61.3, 35.1, 29.8, 25.4. HRMS (ESI) calcd for
C20H19N2O3+ (MH+) 335.1390, found 335.1396.
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2-Hydroxy-2-methyl-5-(pyridin-3-yl)-16-oxa-9azatetracyclo[11.2.1.03,8.05,9] hexadeca-3,5,7,14-tetraen-10-one
(3.20b): General procedure I was performed using 0.50 g (1.5
mmol) of N-(2-acetyl-4-bromophenyl)-3-(furan-2-yl)propanamide (3.10) yielding
0.50 g of a mixture of 5-bromo-8-hydroxy-8-methyl-12-oxa-1azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10-tetraen-16-one (3.19a) and 5-bromo2-hydroxy-2-methyl-16-oxa-9-azatetracyclo[11.2.1.03,8.05,9]hexadeca-3,5,7,14tetraen-10-one (3.20a) in the ratio of 1:1. 0.25 g of the mixture was then subjected to
general procedure for Suzuki coupling SPy using pyridine-3-boronic acid (0.14 g, 1.1
mmol), Pd2(dba)3 (0.014 g, 0.015 mmol), PCy3 (0.012 g, 0.043 mmol), dioxane (2.25
mL), and aqueous K3PO4 (0.73 mmol, 0.97 mL of a 1.27 M solution) resulting in an
isolated yield of 0.071 g, (28%) of 8-hydroxy-8-methyl-5-(pyridin-3-yl)-12-oxa-1azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10-tetraen-16-one (3.19b) and 0.072 g
(30%) of the title compound. 1H NMR (500 MHz, CDCl3) δ 8.84 (s, 1H), 8.63 (s, 1H),
7.87 (dt, J = 8.1, 1.8 Hz, 1H), 7.72 (d, J = 1.9 Hz, 1H), 7.56 (m, 2H), 7.40 (dd, J = 8.0,
4.7 Hz, 1H), 6.37 (dd, J = 5.9, 1.9 Hz, 1H), 5.72 (dd, J = 5.8, 1.1 Hz, 1H), 4.78 (t, J = 1.4
Hz, 1H), 3.57 (s, 1H), 2.95 (dt, J = 17.4, 9.8 Hz, 1H), 2.69 (ddd, J = 17.4, 9.7, 1.8 Hz,
1H), 2.57 (dt, J=13.9, 9.9, 1H), 2.49 (ddd, J=13.9, 9.5, 1.8, 1H), 1.80 (s, 3H).

13

C NMR

(126 MHz, CDCl3) δ 173.0, 148.6, 148.2, 137.1, 136.0, 136.0, 134.8, 134.3, 132.6, 129.3,
129.0, 126.9, 126.4, 123.6, 103.4, 89.2, 78.0, 30.2, 28.5, 24.7. HRMS (ESI) calcd for
C20H19N2O3+ (MH+) 335.1390, found 335.1398.
.
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11-Hydroxy-16-(pyridine-3-yl)-7-oxa-2-azapentacyclo
[9.7.1.02,6.06,10.015,19]nonadeca-1(19),8,15(16),17-tetraen-3one (3.21b): General procedure I was performed using 0.36 g
(0.99 mmol) of N-(4-bromo-8-oxo-5,6,7,8tetrahydronaphthalen-1-yl)-3-(furan-2-yl)propanamide (3.11) yielding a mixture of
11-hydroxy-16-bromo-7-oxa-2-azapentacyclo[9.7.1.02,6.06,10.015,19]nonadeca1(19),8,15(16),17-tetraen-3-one (3.21a) and 10-hydroxy-15-bromo-9-oxa-2azapentacyclo[8.7.1.16,9.02,6.014,18]nonadeca-1(18),7,14(15),16(17)tetraen-3-one
(3.22a) in the ratio of 1:1.9. 0.36 g of the mixture was then subjected to general
procedure SPy using pyridine-3-boronic acid (0.14 g, 1.1 mmol), Pd2(dba)3 (0.011 g,
0.012 mmol), PCy3 (0.078 g, 0.028 mmol), dioxane (3.1 mL), and aqueous K3PO4 (1.70
mmol, 1.34 mL of a 1.27 M solution) resulting in an isolated yield of 0.13 g, (36%) of the
title compound and 0.057 g (16%) of 10-Hydroxy-15-(pyridine-3-yl)-9-oxa-2azapentacyclo[8.7.1.16,9.02,6.014,18]nonadeca-1(18),7,14(15),16(17)tetraen-3-one
(3.22b). 1H NMR (500 MHz, CDCl3) δ 8.52 (dd, J = 4.8, 1.6 Hz, 1H), 8.04 (s, 1H), 7.81
(d, J = 8.2 Hz, 1H), 7.62 (ddd, J = 7.8, 2.3, 1.6 Hz, 1H), 7.32 (ddd, J = 7.8, 4.8, 0.9 Hz,
1H), 7.21 (d, J = 8.2 Hz, 1H), 6.33 (t, J = 2.8 Hz, 1H), 4.76 (dd, J = 3.2, 2.2 Hz, 1H),
3.78 (t, J = 2.4 Hz, 1H), 2.90 (m, 1H), 2.58 (m, 6H), 2.05 (m, 1H), 1.92 (td, J = 13.0, 3.4
Hz, 1H), 1.84 (m, 1H), 1.67 (s, 1H).

13

C NMR (126 MHz, CDCl3) δ 173.4, 149.6, 147.9,

146.8, 136.7, 136.6, 135.7, 135.1, 134.2, 130.0, 129.6, 122.9, 121.5, 101.5, 99.4, 69.5,
60.0, 41.0, 35.2, 29.8, 28.7, 18.4. HRMS (ESI) calcd for C22H21N2O3+ (MH+) 361.1547,
found 361.1550.
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10-Hydroxy-15-(pyridine-3-yl)-9-oxa-2azapentacyclo[8.7.1.16,9.02,6.014,18] nonadeca1(18),7,14(15),16(17)tetraen-3-one (3.22b): General procedure I
was followed using 0.36 g (0.99 mmol) of N-(4-bromo-8-oxo5,6,7,8-tetrahydronaphthalen-1-yl)-3-(furan-2-yl)propanamide (3.11) yielding a
mixture of 11-hydroxy-16-bromo-7-oxa-2azapentacyclo[9.7.1.02,6.06,10.015,19]nonadeca-1(19),8,15(16),17-tetraen-3-one (3.21a)
and 10-hydroxy-15-bromo-9-oxa-2-azapentacyclo[8.7.1.16,9.02,6.014,18]nonadeca1(18),7,14(15),16(17)tetraen-3-one (3.22a) in the ratio of 1:1.9. 0.36 g of the mixture
was then subjected to general procedure SPy using pyridine-3-boronic acid (0.14 g, 1.1
mmol), Pd2(dba)3 (0.011 g, 0.012 mmol), PCy3 (0.078 g, 0.028 mmol), dioxane (3.1 mL),
and aqueous K3PO4 (1.70 mmol, 1.34 mL of a 1.27M solution) resulting in an isolated
yield of 0.13 g, (36%) of 11-hydroxy-16-(pyridine-3-yl)-7-oxa-2azapentacyclo[9.7.1.02,6.06,10.015,19]nonadeca-1(19),8,15(16),17-tetraen-3-one (3.21b)
and 0.057 g (16%) of the title compound. 1H NMR (500 MHz, CDCl3) δ 8.61 (dd,
J=4.9, 1.7, 1H), 8.55 (dd, J=2.3, 0.9, 1H), 7.61 (dt, J=7.8, 2.0, 1H), 7.36 (ddd, J=7.8, 4.9,
0.9, 1H), 7.28 (m, 1H), 7.15 (d, J=8.1, 1H), 6.43 (dd, J=5.8, 1.9, 1H), 5.76 (dd, J=5.9,
1.1, 1H), 4.62 (m, 1H), 3.51 (s, 1H), 3.03 (ddd, J=17.4, 10.3, 9.2, 1H), 2.71 (ddd, J=17.5,
9.6, 1.7, 1H), 2.56 (m, 4H), 2.09 (m, 1H), 1.99 (m, 1H), 1.77 (m, 1H), 1.69 (td, J=13.5,
3.1, 1H). 13C NMR (126 MHz, CDCl3) δ 173.1, 149.9, 148.3, 137.5, 137.3, 136.5, 136.2,
135.3, 133.8, 129.6, 129.3, 126.4, 123.1, 103.2, 88.0, 75.4, 35.8, 30.4, 30.3, 29.7, 28.6,
17.8. HRMS (ESI) calcd for C22H21N2O3+ (MH+) 361.1547, found 361.1553.
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8-Hydroxy-5-pyridin-3-yl-15-pivaloyl-12-oxa-1,15diazatetracyclo [11.3.0.02,7.09,13]heptadeca-2,4,6,10tetraen-17-one (3.23b): General procedure I was followed
using 0.26 g (0.62 mmol) of N-(2-(4-bromo-2formylphenylamino)-2-oxoethyl)-N-(furan-2ylmethyl)pivalamide (3.14) yielding a mixture of 5-bromo-8-hydroxy-15-pivaloyl-12oxa-1,15-diazatetracyclo[11.3.0.02,7.09,13]heptadeca-2,4,6,10-tetraen-17-one (3.23a)
and 5-bromo-2-hydroxy-12-pivaloyl-17-oxa-9,12diazatetracyclo[11.2.1.03,8.05,9]heptadeca-3,5,7,15-tetraen-10-one (3.24a) in the ratio
of 1:1.4. 0.26 g of the mixture was then subjected to general procedure SPy using
pyridine-3-boronic acid (0.086 g, 0.70 mmol), Pd2(dba)3 (0.0063 g, 0.0069 mmol), PCy3
(0.0046 g, 0.016 mmol), dioxane (2.0 mL), and aqueous K3PO4 (1.1 mmol, 0.84 mL of a
1.27 M solution) resulting in an isolated yield of 0.050 g, (19%) of the title compound
and 0.030 g (12%) of 2-hydroxy-12-pivaloyl-5-(pyridin-3-yl)-17-oxa-9,12diazatetracyclo[11.2.1.03,8.05,9]heptadeca-3,5,7,15-tetraen-10-one (3.24b). 1H NMR
(500 MHz, CDCl3) δ 8.53 (d, J = 4.3 Hz, 1H), 8.44 (s, 1H), 7.81 (ddd, J = 7.9, 2.4, 1.6
Hz, 1H), 7.75 (d, J = 8.3 Hz, 1H), 7.54 (dd, J = 8.3, 2.2 Hz, 1H), 7.34 (t, J = 7.8, 4.9 Hz,
1H), 7.32 (d, J = 2.2 Hz, 1H), 6.22 (t, J = 2.7 Hz, 1H), 5.09 (d, J = 18.7 Hz, 1H), 4.76
(dd, J = 3.1, 2.3 Hz, 1H), 4.75 (d, J = 2.2 Hz, 1H), 4.67 (dd, J = 13.9, 1.9 Hz, 1H), 4.14
(d, J = 18.7 Hz, 1H), 3.81 (d, J = 13.9 Hz, 1H), 3.70 (q, J = 2.3 Hz, 1H), 1.66 (s, 1H),1.36
(s, 9H).

13

C NMR (126 MHz, CDCl3) δ 176.5, 164.9, 148.4, 147.9, 146.9, 135.9, 135.5,
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134.6, 134.3, 133.9, 127.9, 127.8, 127.2, 123.6, 99.8, 94.9, 68.9, 55.1, 51.7, 50.2, 38.9,
28.3. HRMS (ESI) calcd for C24H26N3O4+ (MH+) 420.1918, found 420.1921.

2-Hydroxy-12-pivaloyl-5-(pyridin-3-yl)-17-oxa-9,12diazatetracyclo [11.2.1.03,8.05,9]heptadeca-3,5,7,15tetraen-10-one (3.24b): General procedure I was performed
using 0.26 g (0.62 mmol) of N-(2-(4-bromo-2formylphenylamino)-2-oxoethyl)-N-(furan-2ylmethyl)pivalamide (3.14) yielding a mixture of 5-bromo-8-hydroxy-15-pivaloyl-12oxa-1,15-diazatetracyclo[11.3.0.02,7.09,13]heptadeca-2,4,6,10-tetraen-17-one (3.23a)
and 5-bromo-2-hydroxy-12-pivaloyl-17-oxa-9,12diazatetracyclo[11.2.1.03,8.05,9]heptadeca-3,5,7,15-tetraen-10-one (3.24a) in the ratio
of 1:1.4. 0.26 g of the mixture was then subjected to general procedure SPy using
pyridine-3-boronic acid (0.086 g, 0.70 mmol), Pd2(dba)3 (0.0063 g, 0.0069 mmol), PCy3
(0.0046 g, 0.016 mmol), dioxane (2.0 mL), and aqueous K3PO4 (1.1 mmol, 0.84 mL of a
1.27 M solution) resulting in an isolated yield of 0.050 g (19%) of 8-hydroxy-5(pyridin-3-yl)-15-pivaloyl-12-oxa-1,15-diazatetracyclo[11.3.0.02,7.09,13]heptadeca2,4,6,10-tetraen-17-one (3.23b) and 0.030 g (12%) of the title compound. 1H NMR (500
MHz, CDCl3) δ 8.79 (s, 1H), 8.61 (s, 1H), 7.86 (ddd, J = 8.0, 2.4, 1.5 Hz, 1H), 7.52 (dd, J
= 8.3, 2.2 Hz, 1H), 7.43 (d, J = 2.2 Hz, 1H), 7.38 (m, 2H), 6.31 (dd, J = 6.0, 1.8 Hz, 1H),
5.75 (dd, J = 5.9, 1.0 Hz, 1H), 5.16 (m, 1H), 4.92 (dd, J = 18.2, 1.6 Hz, 1H), 4.76 (d, J =
3.6 Hz, 1H), 4.68 (dd, J = 14.0, 1.6 Hz, 1H), 4.26 (d, J = 18.4 Hz, 1H), 3.96 (d, J = 14.0
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Hz, 1H), 3.42 (s, 1H), 1.37 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 176.8, 166.1, 148.8,
148.1, 137.3, 136.3, 135.7, 135.2, 134.3, 134.1, 131.1, 130.3, 128.0, 126.9, 123.6, 96.9,
83.9, 79.1, 49.9, 49.7, 38.9, 28.3. HRMS (ESI) calcd for C24H26N3O4+ (MH+) 420.1918,
found 420.1920.

10-Hydroxy-5-pivaloyl-16-(pyridine-3-yl)-20-oxa-2,5diazapentacyclo [9.7.1.17,10.02,7.015,19]icosa1(19),8,15(16),17(18)tetraen-3,5-dione: General
procedure I was performed using 0.43 g (0.93 mmol) of N(2-(4-bromo-8-oxo-5,6,7,8-tetrahydronaphthalen-1ylamino)-2-oxoethyl)-N-(furan-2-ylmethyl)pivalamide (3.15) yielding a mixture
containing 12-hydroxy-17-bromo-6-pivaloyl-8-oxa-2,5diazapentacyclo[10.7.1.02,7.07,11.016,20]icosa-1(20),9,16(17),18-tetraen-3,6-dione (25a)
and 10-hydroxy-5-pivaloyl-16-bromo-20-oxa-2,5-diazapentacyclo
[9.7.1.17,10.02,7.015,19]icosa-1(19),8,15(16),17(18)tetraen-3,5-dione (3.26a) in the ratio of
1:1.5. 0.43 g of the mixture was then subjected to general procedure SPy using pyridine3-boronic acid (0.21 g, 1.7 mmol), Pd2(dba)3 (0.020 g, 0.022 mmol), PCy3 (0.015 g,
0.053 mmol), dioxane (3 mL), and aqueous K3PO4 (2.7 mmol, 2.1 mL of a 1.27 M
solution) resulting in an isolated yield of 0.086 g, (20%) of the title compound. 1H NMR
(500 MHz, CDCl3) δ 8.62 (d, J = 3.8 Hz, 1H), 8.54 (s, 1H), 7.62 (dt, J = 7.9, 1.9 Hz, 1H),
7.37 (dd, J = 7.8, 4.8 Hz, 1H), 7.09 (m, 2H), 6.36 (dd, J = 5.9, 1.8 Hz, 1H), 5.80 (dd, J =
5.9, 0.9 Hz, 1H), 4.97 (d, J = 18.5 Hz, 1H), 4.73 (m, 2H), 4.30 (d, J = 18.3 Hz, 1H), 3.93
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(d, J = 13.9 Hz, 1H), 3.48 (s, 1H), 2.59 (m, 1H), 2.47 (ddd, J = 17.4, 12.6, 5.5 Hz, 1H),
2.10 (m, 1H), 1.96 (m, 1H), 1.76 (m, 1H), 1.60 (dt, J = 13.5, 2.9 Hz, 1H), 1.39 (s, 9H).
13

C NMR (126 MHz, CDCl3) δ 176.8, 166.2, 149.8, 148.4, 138.4, 137.1, 136.9, 136.5,

136.2, 135.6, 135.2, 129.2, 128.6, 128.2, 123.2, 96.3, 88.4, 75.3, 49.9, 49.1, 38.9, 36.2,
30.4, 28.3, 17.8. HRMS (ESI) calcd for C27H30N3O4+ (MH+) 460.2231, found 460.2234.

10-Hydroxy-5-benzyl-16-(pyridine-3-yl)-20-oxa-2,5diazapentacyclo [9.7.1.17,10.02,7.015,19]icosa1(19),8,15(16),17(18)tetraen-3,5-dione (3.28b): General
procedure I was followed using 0.81 g (1.7 mmol) of Nbenzyl-N-(2-(4-bromo-8-oxo-5,6,7,8tetrahydronaphthalen-1-yl- amino)-2-oxoethyl)furan-2-carboxamide (3.16) forming
mixture of 12-hydroxy-17-bromo-6-benzyl-8-oxa-2,5-diazapentacyclo
[10.7.1.02,7.07,11.016,20]icosa-1(20),9,16(17),18-tetraen-3,6-dione (3.27a) and 10hydroxy-5-benzyl-16-bromo-20-oxa-2,5-diazapentacyclo[9.7.1.17,10.02,7.015,19]icosa1(19),8,15(16),17(18)tetraen-3,5-dione (3.28a) in the ratio of 1:16. 0.20 g of the crude
photoproduct was then subjected to general procedure SPy using pyridine-3-boronic acid
(0.081 g, 0.66 mmol), Pd2(dba)3 (0.0090 g, 0.022 mmol), PCy3 (0.0066 g, 0.024 mmol),
dioxane (1.2 mL), and aqueous K3PO4 (0.42 mmol, 0.56 mL of a 1.27 M solution)
resulting in an isolated yield of 0.072 g, (36%) of the title compound. 1H NMR (500
MHz, CDCl3) δ 8.62 (dd, J = 5.0, 1.7 Hz, 1H), 8.51 (m, 1H), 7.62 (dt, J = 7.8, 2.0 Hz,
1H), 7.40 (m, 6H), 7.13 (d, J = 8.0 Hz, 1H), 7.04 (d, J = 7.9 Hz, 1H), 6.40 (dd, J = 6.0,
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1.8 Hz, 1H), 6.10 (d, J = 5.9 Hz, 1H), 4.96 (d, J = 14.5 Hz, 1H), 4.87 (m, 1H), 4.57 (d, J
= 14.5 Hz, 1H), 4.40 (d, J = 18.2 Hz, 1H), 4.11 (d, J = 18.2 Hz, 1H), 3.16 (s, 1H), 2.59
(m, 1H), 2.47 (ddd, J = 17.5, 12.6, 5.4 Hz, 1H), 2.11 (m, 1H), 1.96 (qdd, J = 13.2, 4.9, 2.5
Hz, 1H), 1.79 (m, 1H), 1.64 (td, J = 13.4, 3.0 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ
167.1, 162.5, 149.8, 148.6, 139.2, 136.9, 136.8, 136.4, 136.1, 135.8, 135.7, 134.6, 129.8,
129.1, 128.5, 128.5, 128.5, 128.4, 123.1, 96.5, 89.6, 75.8, 49.9, 49.8, 36.3, 30.2, 17.7.
HRMS (ESI) calcd for C29H26N3O4+ (MH+) 480.1918, found 480.1927.

8-Hydroxy-5-(thiophen-2-yl)-12-oxa-1azatetracyclo[11.3.0.02,7.09,13] hexadeca-2,4,6,10-tetraen-12one (4h): N-(2-Formyl-4-iodophenyl)-3-(furan-2yl)propanamide (3.3d) (0.42 g, 1.1 mmol) was irradiated
following the general procedure for irradiation yielding 0.42 g of a mixture of 8hydroxy-5-iodo-2-yl-12-oxa-1-azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10tetraen-12-one (4d) and 2-hydroxy-5-iodo-16-oxa-9azatetracyclo[11.2.1.03,8.05,9]hexadeca-3,5,7,14-tetraen-10-one (3.5d) in the ratio 1:1
which was used without further purification. Following the general procedure for Suzuki
coupling STF from 0.20 g (0.54 mmol) of the photoproducts, Pd(PPh3)4 (0.032 g, 0.028
mmol), thiophene-2-boronic acid (0.077 g, 0.60 mmol), NaHCO3 (0.095 g, 1.1 mmol) in
H2O (16 mL) upon flash chromatography 0.030 g (17%) of the title compound and 0.044
g (26%) of 2-hydroxy-5-(thiophen-2-yl)-16-oxa-9azatetracyclo[11.2.1.03,8.05,9]hexadeca-3,5,7,14-tetraen-10-one (3.5h) was isolated.1H
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NMR (500 MHz, CDCl3) δ 7.95 (d, J = 8.3 Hz, 1H), 7.66 (dd, J = 8.3, 2.2 Hz, 1H), 7.48
(d, J = 2.2 Hz, 1H), 7.31 (s, 1H), 7.30 (m, 1H), 7.10 (dd, J = 5.0, 3.7 Hz, 1H), 6.28 (t, J =
2.8 Hz, 1H), 4.83 (t, J = 2.5 Hz, 1H), 4.70 (dd, J = 3.1, 2.2 Hz, 1H), 3.89 (q, J = 2.3 Hz,
1H), 2.88 (ddd, J = 16.6, 10.6, 8.2 Hz, 1H), 2.60 (m, 1H), 2.54 (dd, J = 16.5, 8.9 Hz, 1H),
2.45 (ddd, J = 12.7, 10.6, 8.9 Hz, 1H), 1.90 (m, 1H).

13

C NMR (126 MHz, CDCl3) δ

173.2, 146.7, 143.3, 133.4, 132.0, 131.3, 128.1, 127.0, 126.2, 125.0, 123.6, 123.3, 101.3,
99.3, 70.4, 55.9, 35.1, 29.8. HRMS (ESI) calcd for C18H15LiNO3S+ (MLi+) 332.0927,
found 332.0935.

2-Hydroxy-5-(thiophen-2-yl)-16-oxa-9azatetracyclo[11.2.1.03,8.05,9]hexadeca-3,5,7,14-tetraen-10-one
(3.5h): N-(2-Formyl-4-iodophenyl)-3-(furan-2-yl)propan-amide
(3.3d) (0.42 g, 1.1 mmol) was irradiated following the general
procedure for irradiation yielding 0.42 g of a mixture containing 8-hydroxy-5-iodo-12oxa-1-azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10-tetraen-12-one (3.4d) and 2hydroxy-5-iodo-16-oxa-9-azatetracyclo[11.2.1.03,8.05,9]hexadeca-3,5,7,14-tetraen-10one (3.5d) in the ratio 1:1 which was used without further purification. Following the
general procedure for Suzuki coupling STF from 0.20 g (0.54 mmol) of the
photoproducts, Pd(PPh3)4 (0.032 g, 0.028 mmol), thiophene-2-boronic acid (0.077 g, 0.60
mmol), NaHCO3 (0.095 g, 1.1 mmol) in H2O (16 mL) upon flash chromatography 0.030g
(17%) of 8-hydroxy-5-(thiophen-2-yl)-12-oxa-1azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10-tetraen-12-one (3.4h) and 0.044 g
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(26%) of the title compound was isolated. 1H NMR (500 MHz, CDCl3) δ 7.60 (dd, J =
8.4, 2.2 Hz, 1H), 7.55 (m, 2H), 7.31 (m, 2H), 7.10 (dd, J = 5.1, 3.6 Hz, 1H), 6.36 (dd, J =
5.8, 1.9 Hz, 1H), 5.70 (dd, J = 5.9, 1.1 Hz, 1H), 5.07 (m, 1H), 4.72 (dd, J = 10.8, 3.3 Hz,
1H), 2.93 (m, 2H), 2.69 (ddd, J = 17.4, 9.8, 1.9 Hz, 1H), 2.58 (m, 1H), 2.49 (ddd, J =
13.9, 9.5, 1.9 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 173.1, 143.0, 134.7, 133.6, 132.9,
131.9, 131.6, 129.9, 129.3, 128.1, 126.0, 125.2, 123.4, 103.6, 83.6, 79.3, 30.1, 28.9.
HRMS (ESI) calcd for C18H15LiNO3S+ (MLi+) 332.0927, found 332.0931.

5-(Furan-2-yl)-8-hydroxy-12-oxa-1azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10-tetraen-12one (3.4g): N-(2-Formyl-4-iodophenyl)-3-(furan-2yl)propanamide (3.3d) (0.31 g, 0.84 mmol) was irradiated
following the general procedure for irradiation yielding 0.31 g of a mixture containing 8hydroxy-5-iodo-12-oxa-1-azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10-tetraen-12one (3.4d) and 2-hydroxy-5-iodo-16-oxa-9-azatetracyclo[11.2.1.03,8.05,9]hexadeca3,5,7,14-tetraen-10-one (3.5d) in the ratio of 2.9:1 which was used without further
purification. From 0.31 g (0.83 mmol) of that mixture following the general procedure
for Suzuki coupling STF, using Pd(PPh3)4 (0.056 g, 0.048 mmol), furan-2-boronic acid
(0.11 g, 0.98 mmol), NaHCO3 (0.16 g, 1.9 mmol) in water (27 mL) upon flash
chromatography 0.068 g (27%) of the title compound and 0.10 g (39%) of an inseparable
mixture of 5-(furan-2-yl)-2-hydroxy-16-oxa-9-azatetracyclo[11.2.1.03,8.05,9]hexadeca3,5,7,14-tetraen-10-one (5g) and 4-(furan-2-yl)-15-hydroxy-16-oxa-885

azatetracyclo[10.3.1.02,7.08,12]hexadeca-2,4,6,13-tetraen-9-one (3.29) was isolated. 1H
NMR (500 MHz, CDCl3) δ 7.94 (d, J = 8.4 Hz, 1H), 7.70 (dd, J = 8.4, 2.0 Hz, 1H), 7.57
(d, J = 2.0 Hz, 1H), 7.48 (dd, J = 1.8, 0.7 Hz, 1H), 6.66 (dd, J = 3.3, 0.8 Hz, 1H), 6.50
(dd, J = 3.4, 1.8 Hz, 1H), 6.26 (t, J = 2.8 Hz, 1H), 4.83 (d, J = 2.2 Hz, 1H), 4.68 (dd, J =
3.0, 2.2 Hz, 1H), 3.88 (m, 1H), 2.87 (ddd, J = 16.3, 10.4, 8.2 Hz, 1H), 2.52 (m, 4H).

13

C

NMR (126 MHz, CDCl3) δ 173.2, 153.1, 146.7, 142.2, 133.2, 131.2, 128.5, 125.0, 124.0,
123.5, 111.8, 105.2, 101.4, 99.3, 70.4, 55.9, 35.1, 29.8. HRMS (ESI) calcd for
C18H16NO4+ (MH+) 310.1074, found 310.1081.

4-(Furan-2-yl)-15-hydroxy-16-oxa-8azatetracyclo[10.3.1.02,7.08,12] hexadeca-2,4,6,13-tetraen-9one (3.29): N-(2-Formyl-4-iodophenyl)-3-(furan-2yl)propanamide (3.3d) (0.31 g, 0.84 mmol) was irradiated
following the general procedure for irradiation yielding 0.31 g of a mixture containing 8hydroxy-5-iodo-12-oxa-1-azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10-tetraen-12one (4d) and 2-hydroxy-5-iodo-16-oxa-9-azatetracyclo[11.2.1.03,8.05,9]hexadeca3,5,7,14-tetraen-10-one (3.5d) in the ratio of 2.9:1 which was used without further
purification. From 0.31 g (0.83 mmol) of that mixture following the general procedure
for Suzuki coupling, using Pd(PPh3)4 (0.056 g, 0.048 mmol), furan-2-boronic acid (0.11
g, 0.98 mmol), NaHCO3 (0.16 g, 1.9 mmol) in water (27 mL) upon flash chromatography
0.068 g (27%) of 5-(furan-2-yl)-8-hydroxy-12-oxa-1azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10-tetraen-12-one (3.4g) and 0.10 g
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(39%) of an inseparable mixture of 5-(furan-2-yl)-2-hydroxy-16-oxa-9azatetracyclo[11.2.1.03,8.05,9]hexadeca-3,5,7,14-tetraen-10-one (3.5g) and 4-(furan-2yl)-15-hydroxy-16-oxa-8-azatetracyclo[10.3.1.02,7.08,12]hexadeca-2,4,6,13-tetraen-9one (3.29). A mixture of 5-(furan-2-yl)-2-hydroxy-16-oxa-9azatetracyclo[11.2.1.03,8.05,9]hexadeca-3,5,7,14-tetraen-10-one (3.5g) and 4-(furan-2yl)-15-hydroxy-16-oxa-8-azatetracyclo[10.3.1.02,7.08,12]hexadeca-2,4,6,13-tetraen-9one (3.29) (0.093 g, 0.30 mmol) in 4 nmL of DMSO was placed in a glycerol bath at 160
°C for 60 min. The solution was allowed to cool, concentrated, and the remaining mixture
subjected to flash chromatography resulting in an isolated yield of 0.043 g of the title
compound. 1H NMR (500 MHz, CDCl3) δ 8.38 (d, J = 8.7 Hz, 1H), 7.63 (dd, J = 8.6, 2.0
Hz, 1H), 7.51 (d, J = 2.0 Hz, 1H), 7.48 (dd, J = 1.9, 0.8 Hz, 1H), 6.64 (dd, J = 3.4, 0.8
Hz, 1H), 6.50 (dd, J = 3.4, 1.8 Hz, 1H), 6.11 (ddd, J = 9.7, 5.3, 1.2 Hz, 1H), 5.86 (m,
1H), 5.23 (s, 1H), 4.03 (d, J = 5.2 Hz, 1H), 2.74 (m, 2H), 2.40 (m, 2H), 2.28 (s, 1H). 13C
NMR (126 MHz, CDCl3) δ 170.9, 153.1, 142.2, 131.6, 129.5, 127.1, 127.0, 124.1, 123.5,
120.6, 120.2, 111.8, 105.0, 86.1, 78.1, 66.8, 30.3, 29.9. HRMS (ESI) calcd for
C18H15LiNO4+ (MLi+) 316.1156, found 316.1164.
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X-Ray Structures
X-Ray structures were obtained with a Bruker APEX II instrument and the structure was refined
using XShell software. The goodness of fit “S” is listed after each entry.
1. 8-Hydroxy-5-phenyl-12-oxa-1-azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10-

tetraen-16-one (3.4f) S = 0.891

2. 11-Hydroxy-16-(pyridine-3-yl)-7-oxa-2-azapentacyclo

[9.7.1.02,6.06,10.015,19]nonadeca-1(19),8,15(16),17-tetraen-3-one (3.21b) S = 0.907
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3. 10-Hydroxy-15-(pyridine-3-yl)-9-oxa-2-

azapentacyclo[8.7.1.16,9.02,6.014,18]nonadeca-1(18),7,14(15),16(17)tetraen-3-one
(3.22b) S = 0.747

4. 8-Hydroxy-6-(pyridin-3-yl)-12-oxa-1-azatetracyclo[11.3.0.02,7.09,13] hexadeca-

2,4,6,10-tetraen-16-one (3.17b) S = 1.109

2,7

9,13

5. 5-(Furan-2-yl)-8-hydroxy-12-oxa-1-azatetracyclo[11.3.0.0 .0

2,4,6,10-tetraen-12-one (3.4g) S = 0.876
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]hexadeca-

6. 5-(furan-2-yl)-2-hydroxy-16-oxa-9-azatetracyclo[11.2.1.03,8.05,9]hexadeca-

3,5,7,14-tetraen-10-one (3.5g) S = 0.859
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Chapter 4: o-Azaxylylene Cascade Reactions
Diversity oriented synthesis aims to probe the greatest region of chemical space
possible9, and this is best accomplished through modifications to the core framework
which significantly change the overall topology of a molecule. This chapter focuses on
the first reported case of o-azaxylylene cascade reactions in the excited state. Not only
does this approach yield a significantly unique topology in keeping with DOS, but also
forms multiple fused sp3 ring systems, which can be synthesized in a one-pot two-step
fashion, from affordable starting materials, and obtained without column
chromatography. These products contain many stereogenic centers, have a large fraction
of sp3 carbons, few rotatable bonds, and multiple fused bridges which are all
characteristics of active pharmaceuticals derived from natural products.6

Introduction
Cascade reactions have been shown to be a prominent method from which nature
generates this selectivity.38 Polycyclic structures with multiple stereocenters generated
from linear achiral precursors are a stunning example of this phenomena, and is
demonstrated in the electrophilic cascade leading to the formation of terpenes,39 such as
the steroid precursor lanosterol illustrated in Figure 4.1.
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Figure 4.1

Cascade reactions are often regarded as an “environmentally friendly means to
generate molecular complexity”40 in the formation of natural or designed products.
However, implementation of this methodology on the bench top does pose some
challenges, as cascade reactions by their very nature rely on the formation of highly
reactive, short-lived intermediates in minute quantities without any spatial
compartmentalization of sequential processes making the control over the reaction
difficult, if not impossible. These reactions are not only attractive from the standpoint of
synthesizing natural or designed products, but also have the potential to serve as powerful
tools in the exploration of chemical space.
Herein we set out to utilize two photochemically generated o-azaxylylene
intermediates, resulting from the excited state intramolecular proton transfer of o-amido
aldehydes and ketones, in a cascade reaction that results in a rapid growth in complexity
to yield novel fused ring systems.

Results and Discussion
Photoprecursors were equipped with two reactive o-acylanilid moieties, each of
which can form o-azaxylylenes upon irradiation and potentially react with a dieneophile.
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The system was designed so that the first o-azaxylylene addition to the tethered furan
pendant would bring the second tethered o-azaxylylene into close spatial proximity so
that it could react with the newly formed 2,5- or 3,4-dihydrofuran moiety generated from
the first addition (Scheme 4.1)

Scheme 4.1

In order to introduce two azaxylylene pendants into one framework, a two-step
one-pot procedure was developed (Scheme 4.2): (i) acetylation of isatin (4.1) with
furanpropanoic acids 4.2 or 4.3 followed by (ii) ring opening with anilines 4.6a-d.
Photoprecursors 4.7b-d were obtained after workup, while photoprecursors 4.7a and 4.8a
required an additional oxidation step with PCC to yield the aldehyde products.
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Scheme 4.2

Photoprecursors (4.7a-d, 4.8a) are characterized by the maximum UV absorption
between 350-365 nm, and were irradiated using a Rayonet broadband 300-400 nm UV
source yielding photoproducts 4.9-14 in moderate to good yields. The reaction was
found to be substantially slower for photoprecursors bearing one reactive o-azaxylylene
core21, with an absolute quantum yield of cyclization for the irradiation of 4.7b being <
0.02.
Irradiation of photoprecursors 4.7a-d yielded three products (Scheme 4.3): (i) [4
+ 4] or “single click” cyclization products 4.9a-d, (ii) [4 + 2]/[4 + 2] or “double click”
cascade products 4.10a-d, and (iii) [4 + 2]/disproportion or “1.5 click” cascade products
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4.11a-d. Irradiation of photoprecursor 4.8a yielded only the single click [4 + 4] (4.12)
and [4 + 2]/[4 + 2] double click (4.13) products. The photoproduct of [4 + 4] cyclization
likely does not undergo a cascade reaction because of the unfavorable spatial
arrangement between the o-azaxylyene core and the double bond resulting from the initial
cycloaddition.
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Scheme 4.3

It is likely that the double click and disproportionation products are derived from
an initial [4 + 2] cyclization. When monitoring the reaction by 1H NMR, the
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accumulation and subsequent disappearance of a single click [4 + 2] cyclization is
observed, and this disappearance is likely the result of the [4 + 2] cycloaddition product
being consumed through the double click and disproportionation channels. Given these
observations and the previous work on the mechanism of o-azaxylylene cycloaddition21,
the double click and disproportionation process is postulated to proceed through
excitation to S1, followed by excited state intramolecular proton transfer, intersystem
crossing to the triplet state, and a step-wise addition to the furan pendant starting with the
N-centered attack and finishing with radical recombination to reach the single click [4 +
2] product. At this point, the same process occurs with the second pendant; however,
after the initial attack on the double bond the second radical can do one of two things: (a)
radical recombination forming the double click product, or (b) hydrogen abstraction from
the OH group reforming the o-amido ketone or aldehyde leading to the 1.5 click product
(Scheme 4.4).
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Scheme 4.4

In all cases only one diastereomer was observed, and the stereochemistry was
assigned using NOE experiments (Figure 4.2). For compound 4.10b irradiation of the
methyl group results in the enhancement of Hb (2.2%) and Ha (0.8%) signals. Irradiation
of OH-b does not result in the enhancement of any proton signals, and the irradiation of
OH-a results in the enhancement of Hc (3%). This suggests that Ha, Hb, and Hc, and
OH-a are on the same face. Compound 4.11b showed signal enhancement of He (12%)
upon irradiation of Hd, implying that these protons are on the same face. The 1NMR
spectra are in agreement with calculations using a relativistic force field method
developed by Kutateladze et al.41
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Figure 4.2

Experimental
Common solvents were purchased from Pharmco and used as is, except for THF,
which was refluxed over and distilled from potassium benzophenone ketyl prior to use.
Common reagents were purchased from Aldrich or TCI America and used without
additional purification, unless indicated otherwise. NMR spectra were recorded at 25°C
on a Bruker Avance III 500 MHz in CDCl3 with TMS as an internal standard (unless
noted otherwise). High resolution mass spectra were obtained on the MDS
SCIEX/Applied Biosystems API QSTARTM Pulsar i Hybrid LC/MS/MS System mass
spectrometer by Dr. Jeremy Balsbaugh at the University of Colorado at Boulder. Flash
column chromatography was performed using Teledyne Ultra Pure Silica Gel (230 – 400
mesh) on a Teledyne Isco Combiflash Rf using Hexanes/EtOAc or DCM/Methanol as
eluents. 8-Amino-1-tetralone42 and 1-(2-amino-5-bromophenyl)ethanone36 were
synthesized according to the published procedures.
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Synthesis of photoprecursors

General procedure for isatin coupling (A): Isatin (1 mmol) was added to the
solution of carboxylic acid (1.2 mmol) in DCM (4 mL) at 0 °C, followed by EDC (1.2
mmol) and DMAP (0.10 mmol). The reaction mixture was allowed to stir at room
temperature for three hours, followed by the addition of the amine (1.2 mmol) and left
stirring overnight. The mixture was diluted with DCM (14 mL), and washed with 5% aq.
HCl, water, a solution of sat. aq. NaHCO3, and water (6 mL each). The organic layer was
dried over anh. Na2SO4, filtered, concentrated, and purified by flash chromatography
(Hex/EtOAc) yielding the desired product.

General procedure for the oxidation of alcohols to aldehydes (B): To a stirred
mixture of the alcohol (1 mmol) in dry DCM (8 mL) was added PCC (1.6 mmol). The
reaction mixture was left stirring overnight, filtered through a layer of silica gel using
CH2Cl2/3% MeOH, (100 mL) as an eluent, concentrated, and purified by flash
chromatography (Hex/EtOAc) yielding the isolated desired product.
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N-(2-(((2-Formylphenyl)carbamoyl]carbonyl)phenyl)-3(furan-2-yl)propanamide (4.7a) : Following general procedure
A, from furanpropanoic acid (0.34 g, 2.4 mmol), isatin (0.30 g,
2.0 mmol), EDC (0.47 g, 2.5 mmol), DMAP (0.025 g, 0.20
mmol), and 2-aminobenzyl alcohol (0.30 g, 2.4 mmol) in DCM
(12 mL) upon workup 3-(furan-2-yl)-N-[2-(((2(hydroxymethyl)phenyl)carbamoyl)carbonyl)phenyl)propanamide (0.78 g, crude)
was obtained, and used in the next step without further purification. 1H NMR (500 MHz,
CDCl3) δ 11.01 (s, 1H), 10.12 (s, 1H), 8.74 (dd, J = 8.6, 1.2 Hz, 1H), 8.54 (dd, J = 8.1,
1.5 Hz, 1H), 8.32 (dd, J = 8.1, 1.1 Hz, 1H), 7.67 (ddd, J = 8.8, 7.5, 1.6 Hz, 1H), 7.45 (td,
J = 7.8, 1.6 Hz, 1H), 7.34 (dd, J = 1.9, 0.9 Hz, 1H), 7.27 (d, J = 1.4 Hz, 1H), 7.20 (m,
2H), 6.30 (dd, J = 3.2, 1.9 Hz, 1H), 6.10 (dd, J = 3.3, 0.8 Hz, 1H), 4.86 (d, J = 5.5 Hz,
2H), 3.12 (t, J = 7.6 Hz, 2H), 2.84 (dd, J = 7.8, 6.4 Hz, 2H), 2.28 (t, J = 5.6 Hz, 1H)
General procedure B was followed using 3-(furan-2-yl)-N-[2-(((2(hydroxymethyl)phenyl)carbamoyl)carbonyl)phenyl)propanamide (0.78 g), and PCC
(0.64 g, 3.0 mmol) in DCM (50 mL). Upon purification by flash chromatography 0.31 g
(40% over two steps) of the title compound was isolated. 1H NMR (500 MHz, CDCl3) δ
12.35 (s, 1H), 11.06 (s, 1H), 10.05 (d, J = 0.8 Hz, 1H), 8.87 (d, J = 8.4 Hz, 1H), 8.79 (dd,
J = 8.6, 1.1 Hz, 1H), 8.45 (dd, J = 8.1, 1.6 Hz, 1H), 7.82 (dd, J = 7.6, 1.7 Hz, 1H), 7.74
(m, 1H), 7.68 (ddd, J = 8.8, 7.2, 1.6 Hz, 1H), 7.41 (td, J = 7.5, 1.0 Hz, 1H), 7.36 (dd, J =
1.9, 0.9 Hz, 1H), 7.19 (ddd, J = 8.2, 7.3, 1.2 Hz, 1H), 6.30 (dd, J = 3.2, 1.9 Hz, 1H), 6.12
(m, 1H), 3.14 (t, J = 7.6 Hz, 2H), 2.88 (dd, J = 8.3, 6.8 Hz, 2H).
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13

C NMR (126 MHz,

CDCl3) δ 195.2, 190.4, 171.0, 161.3, 153.9, 142.5, 141.3, 139.2, 136.8, 136.2, 136.1,
134.3, 124.4, 122.8, 122.5, 121.0, 120.3, 118.4, 110.2, 105.6, 36.8, 23.7. HRMS (ESI)
calcd for C22H19BrN2O5+ (MH+) 391.1288, found 391.1299.

N-(2-(((2-Formylphenyl)carbamoyl)carbonyl)phenyl)3-(5-(2-(trifluoromethyl)phenyl)furan-2yl)propanamide (4.8a): Following general procedure A,
from 3-(5-(2-(trifluoromethyl)phenyl)furan-2yl)propionic acid (0.90 g, 3.2 mmol), isatin (0.39 g, 2.7
mmol), EDC (0.61 g, 3.2 mmol), DMAP (0.032 g, 0.26 mmol), and 2-aminobenzyl
alcohol (0.39 g, 3.2 mmol) in DCM (40 mL) N-(2-(((2(hydroxymethyl)phenyl)carbamoyl)carbonyl)phenyl)-3-(5-(2(trifluoromethyl)phenyl)furan-2-yl)propanamide
(1.72 g, crude) was obtained, and used in the next step without further
purification. 1H NMR (500 MHz, CDCl3) δ 11.06 (s, 1H), 10.15 (s, 1H), 8.75 (dd, J =
8.5, 1.1 Hz, 1H), 8.53 (dd, J = 8.2, 1.6 Hz, 1H), 8.30 (dd, J = 8.2, 1.2 Hz, 1H), 7.73 (m,
2H), 7.67 (ddd, J = 8.8, 7.3, 1.6 Hz, 1H), 7.53 (m, 1H), 7.43 (td, J = 8.0, 1.5 Hz, 1H),
7.38 (m, 1H), 7.26 (dd, J = 8.2, 1.2 Hz, 1H), 7.20 (m, 2H), 6.64 (d, J = 3.4 Hz, 1H), 6.23
(d, J = 3.4 Hz, 1H), 4.83 (s, 2H), 3.20 (t, J = 7.5 Hz, 2H), 2.90 (dd, J = 8.4, 6.8 Hz, 2H).
General procedure B was followed using N-(2-(((2(hydroxymethyl)phenyl)carbamoyl)carbonyl)phenyl)-3-(5-(2(trifluoromethyl)phenyl)furan-2-yl)propanamide (1.72 g), and PCC (1.04 g, 4.82
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mmol) in DCM (50 mL). Upon purification by flash chromatography 0.36 g (25 % over
two steps) of the title compound was obtained. 1H NMR (500 MHz, CDCl3) δ 12.33 (s,
1H), 11.10 (s, 1H), 10.03 (d, J = 0.7 Hz, 1H), 8.86 (d, J = 8.4 Hz, 1H), 8.79 (dd, J = 8.7,
1.1 Hz, 1H), 8.45 (dd, J = 8.1, 1.6 Hz, 1H), 7.81 (dd, J = 7.6, 1.6 Hz, 1H), 7.74 (m, 3H),
7.68 (ddd, J = 8.7, 7.4, 1.6 Hz, 1H), 7.54 (m, 1H), 7.40 (td, J = 7.5, 1.0 Hz, 1H), 7.37 (m,
1H), 7.20 (ddd, J = 8.2, 7.3, 1.2 Hz, 1H), 6.65 (d, J = 3.3 Hz, 1H), 6.25 (dt, J = 3.3, 0.9
Hz, 1H), 3.22 (t, J = 7.5 Hz, 2H), 2.94 (dd, J = 8.3, 6.8 Hz, 2H). 13C NMR (126 MHz,
CDCl3) δ 195.2, 190.4, 170.9, 161.2, 154.7, 149.2, 142.4, 139.2, 136.8, 136.2, 136.1,
134.3, 131.6, 129.8 (q, J = 1.9 Hz, 1C), 129.5, 127.2, 126.6 (q, J = 6.0 Hz, 1C), 126.0 (q,
J = 31.2 Hz, 1C), 124.5, 124.1 (q, J = 273.8 Hz, 1C), 122.8, 122.5, 121.1, 120.2, 118.4,
111.0(q, J = 3.6 Hz, 1C), 108.0, 36.6, 23.8. HRMS (ESI) calcd for C29H22F3N2O5+
(MH+) 535.1475, found 535.1496.

N-(2-(((2-Acetylphenyl)carbamoyl)carbonyl)phenyl)-3(furan-2-yl)propanamide (4.7b): Following general procedure
A, from furanpropanoic acid (1.71 g, 12.2 mmol), isatin (1.50 g,
12.2 mmol), EDC (2.35 g, 12.3 mmol), DMAP (0.12 g, 0.98
mmol), and 2’-aminoacetophenone (1.65 g, 12.2 mmol) in DCM
(45 mL) upon purification by flash chromatography 2.08 g (50 %) of the title compound
was isolated. 1H NMR (500 MHz, CDCl3) δ 12.93 (s, 1H), 11.10 (s, 1H), 8.87 (dd, J =
8.4, 1.2 Hz, 1H), 8.78 (dd, J = 8.5, 1.2 Hz, 1H), 8.43 (dd, J = 8.1, 1.6 Hz, 1H), 8.02 (dd, J
= 8.0, 1.6 Hz, 1H), 7.67 (m, 2H), 7.35 (dd, J = 1.9, 0.9 Hz, 1H), 7.29 (m, 1H), 7.18 (ddd,
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J = 8.3, 7.2, 1.2 Hz, 1H), 6.30 (dd, J = 3.2, 1.8 Hz, 1H), 6.10 (m, 1H), 3.13 (t, J = 7.5 Hz,
2H), 2.86 (dd, J = 8.4, 6.6 Hz, 2H), 2.74 (s, 3H).
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C NMR (126 MHz, CDCl3) δ 202.8,

191.0, 171.0, 161.4, 154.0, 142.4, 141.3, 139.4, 136.7, 135.2, 134.3, 131.9, 123.9, 122.9,
122.5, 121.0, 121.0, 118.4, 110.2, 105.6, 36.7, 28.5, 23.7. HRMS (ESI) calcd for
C23H21N2O5+ (MH+) 405.1445, found 405.1454.

N-(2-(((2-Acetyl-4bromophenyl)carbamoyl)carbonyl)phenyl)-3-(furan-2yl)propanamide (4.7c): Following general procedure A, from
furanpropanoic acid (1.14 g, 8.13 mmol), isatin (1.00 g, 6.80
mmol), EDC (1.56 g, 8.14 mmol), DMAP (0.083 g, 0.68 mmol),
and 1-(2-amino-5-bromophenyl)ethanone (1.75 g, 8.18 mmol) in DCM (30 mL) upon
purification by flash chromatography 0.81 g (25 %) of the title compound was isolated.
1

H NMR (500 MHz, CDCl3) δ 12.83 (s, 1H), 11.05 (s, 1H), 8.81 (d, J = 9.0 Hz, 1H), 8.78

(dd, J = 8.6, 1.1 Hz, 1H), 8.43 (dd, J = 8.1, 1.6 Hz, 1H), 8.11 (d, J = 2.3 Hz, 1H), 7.77
(dd, J = 8.9, 2.3 Hz, 1H), 7.67 (ddd, J = 8.7, 7.2, 1.7 Hz, 1H), 7.35 (dd, J = 1.9, 0.9 Hz,
1H), 7.19 (ddd, J = 8.2, 7.2, 1.2 Hz, 1H), 6.30 (dd, J = 3.2, 1.9 Hz, 1H), 6.11 (m, 1H),
3.13 (t, J = 7.5 Hz, 2H), 2.86 (dd, J = 8.3, 6.8 Hz, 2H), 2.74 (s, 3H).
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C NMR (126

MHz, CDCl3) δ 201.6, 190.5, 171.0, 161.2, 153.9, 142.5, 141.3, 138.3, 137.8, 136.8,
134.5, 134.3, 124.3, 122.6, 122.5, 121.0, 118.3, 116.5, 110.2, 105.6, 36.7, 28.6, 23.7.
HRMS (ESI) calcd for C23H20BrN2O5+ (MH+) 483.0550, found 483.0557.
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3-(Furan-2-yl)-N-(2-(((8-oxo-5,6,7,8-tetrahydronaphthalen-1yl)carbamoyl)carbonyl)phenyl)propanamide (4.7d): Following
general procedure A, from furanpropanoic acid (0.62 g, 4.4
mmol), isatin (0.55 g, 3.7 mmol), EDC (0.85 g, 4.4 mmol),
DMAP (0.045 g, 0.37 mmol), and 8-aminotetralone (0.72 g, 4.5
mmol) in DCM (50 mL) upon purification by flash chromatography 0.57 g (35%) of the
title compound was isolated. 1H NMR (500 MHz, CDCl3) δ 13.35 (s, 1H), 11.14 (s, 1H),
8.79 (dd, J = 8.5, 1.2 Hz, 1H), 8.73 (d, J = 8.4 Hz, 1H), 8.42 (dd, J = 8.1, 1.6 Hz, 1H),
7.66 (ddd, J = 8.7, 7.3, 1.6 Hz, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.35 (dd, J = 2.0, 0.9 Hz,
1H), 7.18 (ddd, J = 8.3, 7.2, 1.2 Hz, 1H), 7.10 (m, 1H), 6.30 (dd, J = 3.2, 1.9 Hz, 1H),
6.10 (m, 1H), 3.14 (t, J = 7.6 Hz, 2H), 3.06 (t, J = 6.1 Hz, 2H), 2.86 (dd, J = 8.4, 6.8 Hz,
2H), 2.78 (dd, J = 7.1, 6.2 Hz, 2H), 2.16 (p, J = 6.4 Hz, 2H).
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C NMR (126 MHz,

CDCl3) δ 203.4, 191.2, 171.0, 161.5, 154.0, 146.5, 142.4, 141.3, 140.3, 136.6, 135.1,
134.3, 124.7, 122.4, 120.9, 119.4, 118.6, 118.4, 110.2, 105.5, 40.6, 36.7, 30.9, 23.7, 22.7.
HRMS (ESI) calcd for C25H23N2O5+ (MH+) 431.1601, found 431.1612.

Photochemical reactions
General procedure for irradiation (C): Solutions with ca. 4 mM of the
photoprecursors in DCM were degassed with N2 and irradiated in Pyrex or borosilicate
glass reaction vessels in a Rayonet reactor equipped with RPR-3500 UV lamps
(broadband 300-400 nm UV source with peak emission at 350 nm) until consumption of
the starting material and [4 + 2] cycloaddition products was observed, as determined by
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H NMR. Specific purification procedures are listed below the compound of interest.

When purification by chromatography was necessary compounds were separated using
silica gel with DCM and MeOH as an eluent.

Irradiation of N-(2-(((2-formylphenyl)carbonyl)phenyl)-3-(furan-2-yl)propanamide
(4.7a): General procedure C was followed using 0.28 g of 4.7a (0.72 mmol) in DCM
(250 mL). Irradiation of N-(2-(((2-formylphenyl)carbonyl)phenyl)-3-(furan-2yl)propanamide (4.7a)The mixture was purified by flash chromatography yielding pure
14,23-dihydroxy-2-oxa-7,16diazaheptacyclo[11.9.2.03,7.03,25.08,13.016,24.017,22]pentacos-17(18),19(20),21(22)hexaene-6,15-dione (4.10a) (0.093 g, 33%), 5-(2-formylphenyl)-2-oxa,5,14-diazapentacyclo[10.5.1.01,14.04,8.08,13]octadec-8(9),10(11),12(13)-triene-6,15-dione (4.11a)
(0.021 g, 8%), and N-(2-formylphenyl)-12-hydroxy-4-oxo-16-oxa-5azatetracyclo[11.2.1.0¹,⁵.0⁶,¹¹]hexadeca-6,8,10,14-tetraene-12-carboxamide (4.9a)
(0.036 g, 13%).

4.10a: 1H NMR (500 MHz, CDCl3) δ 8.35 (m, 2H), 7.69 (dd, J
= 7.9, 1.2 Hz, 1H), 7.50 (td, J = 7.7, 1.5 Hz, 1H), 7.40 (m, 2H),
7.31 (m, 1H), 7.20 (ddd, J = 8.6, 7.4, 1.3 Hz, 1H), 4.83 (d, J =
5.6 Hz, 1H), 4.63 (dd, J = 9.0, 6.8 Hz, 1H), 4.40 (dd, J = 6.8, 5.7
Hz, 1H), 3.48 (d, J = 9.0 Hz, 1H), 3.35 (s, 1H), 2.89 (dt, J =
17.1, 9.6 Hz, 1H), 2.54 (m, 2H), 2.34 (m, 2H).
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13

C NMR (126 MHz, DMSO) δ 174.3,

171.2, 136.0, 133.3, 133.2, 129.9, 129.5, 128.8, 128.6, 127.0, 126.3, 124.1, 122.8, 119.2,
98.9, 74.2, 71.8, 65.0, 61.0, 51.3, 31.8, 30.3. HRMS (ESI) calcd for C22H19N2O5+ (MH+)
391.1288, found 391.1293.

4.11a: 1H NMR (500 MHz, CDCl3) δ 9.91 (s, 1H), 8.33 (dd, J = 8.2,
1.3 Hz, 1H), 8.15 (dd, J = 8.0, 1.6 Hz, 1H), 8.00 (dd, J = 7.7, 1.6 Hz,
1H), 7.72 (td, J = 7.7, 1.6 Hz, 1H), 7.61 (td, J = 7.6, 1.1 Hz, 1H),
7.48 (m, 1H), 7.27 (m, 2H), 4.89 (ddd, J = 9.4, 6.0, 3.9 Hz, 1H), 3.88
(dd, J = 10.3, 6.0 Hz, 1H), 3.78 (dd, J = 10.3, 3.8 Hz, 1H), 3.71 (d, J
= 9.0 Hz, 1H), 3.43 (s, 1H), 2.83 (dt, J = 17.1, 9.5 Hz, 1H), 2.51 (ddd, J = 17.2, 9.6, 2.2
Hz, 1H), 2.45 (ddd, J = 13.2, 9.3, 2.3 Hz, 1H), 2.32 (dt, J = 13.2, 9.6 Hz, 1H).

13

C NMR

(126 MHz, CDCl3) δ 189.4, 174.2, 173.0, 137.5, 135.1, 133.6, 132.8, 132.1, 130.3, 128.6,
127.9, 127.1, 126.6, 125.7, 121.6, 98.3, 71.8, 69.2, 62.8, 54.5, 31.2, 29.7. HRMS (ESI)
calcd for C22H19N2O5+ (MH+) 391.1288, found 391.1301.

4.9a: 1H NMR (500 MHz, CDCl3) δ 12.56 (s, 1H), 10.02 (s,
1H), 8.96 (d, J = 8.4 Hz, 1H), 7.80 (dd, J = 7.7, 1.7 Hz, 1H), 7.72
(ddd, J = 8.8, 7.7, 1.7), 7.48 (dd, J = 7.8, 1.1 Hz, 1H), 7.37 (m,
2H), 7.18 (m, 2H), 6.74 (dd, J = 5.8, 2.0 Hz, 1H), 5.72 (dd, J =
5.8, 1.1 Hz, 1H), 4.90 (dd, J = 2.0, 1.1 Hz, 1H), 4.61 (s, 1H),
2.85 (dt, J = 17.3, 9.7 Hz, 1H), 2.66 (ddd, J = 17.3, 9.6, 1.6 Hz, 1H), 2.56 (dt, J = 13.9,
9.9 Hz, 1H), 2.47 (ddd, J = 13.8, 9.4, 1.6 Hz, 1H).
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13

C NMR (126 MHz, CDCl3) δ 194.6,

173.2, 171.3, 139.3, 136.9, 136.1, 135.9, 133.8, 133.2, 129.4, 128.7, 128.5, 128.0, 126.8,
123.9, 123.0, 120.0, 104.1, 85.4, 85.0, 30.0, 28.8. HRMS (ESI) calcd for C22H18LiN2O5+
(MH+) 397.1370, found 397.1380.

Irradiation of N-(2-(((2-formylphenyl)carbamoyl)carbonyl)phenyl)-3-(5-(2(trifluoromethyl)phenyl)furan-2-yl)propanamide (4.8a): General procedure C was
followed using 0.32 g of 4.8a (0.60 mmol) in DCM (250 mL). The mixture was purified
by flash chromatography yielding pure 14,23-Dihydroxy-1-(2(trifluoromethyl)phenyl)-2-oxa-7,16diazaheptacyclo[11.9.2.03,7.03,25.08,13.016,24.017,22]pentacos-17(18),19(20),21(22)hexaene-6,15-dione (4.13) (0.042 g, 13%), and N-(2-formylphenyl)-12-hydroxy-4-oxo13-[2-(trifluoromethyl)phenyl]-16-oxa-5-azatetracyclo[11.2.1.0¹,⁵.0⁶,¹¹]hexadeca6,8,10,14-tetraene-12-carboxamide (4.12) (0.030 g, 9%).

4.13: 1H NMR (500 MHz, DMSO) δ 8.20 (dd, J = 8.0, 1.6 Hz,
1H), 8.16 (dd, J = 8.3, 1.3 Hz, 1H), 7.88 (dd, J = 7.9, 1.5 Hz,
1H), 7.55 (dd, J = 7.8, 1.3 Hz, 1H), 7.49 (m, 2H), 7.44 (td, J =
7.9, 1.2 Hz, 1H), 7.35 (ddd, J = 8.8, 7.3, 1.6 Hz, 1H), 7.16 (td, J
= 7.5, 1.3 Hz, 1H), 7.12 (ddd, J = 8.5, 7.3, 1.3 Hz, 1H), 7.01
(dd, J = 7.4, 1.4 Hz, 1H), 6.95 (d, J = 8.0 Hz, 1H), 6.56 (s, 1H), 5.47 (d, J = 9.5 Hz, 1H),
4.39 (d, J = 2.3 Hz, 1H), 3.86 (d, J = 2.3 Hz, 1H), 3.53 (d, J = 9.3 Hz, 1H), 2.59 (dt, J =
18.7, 9.5 Hz, 1H), 2.43 (dd, J = 17.2, 9.5 Hz, 1H), 2.22 (dt, J = 13.5, 9.9 Hz, 1H), 1.79
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(ddd, J = 13.7, 9.7, 1.7 Hz, 1H).

13

C NMR (126 MHz, DMSO) δ 173.4, 172.6, 141.6,

137.2, 133.8, 133.0, 132.0, 130.2, 129.9, 129.4, 129.1, 128.9, 128.9, 128.7, 127.4, 125.8,
124.9, 121.0, 101.7, 88.8, 74.6, 70.8, 66.5, 54.4, 40.1, 32.8, 29.4. HRMS (ESI) calcd for
C29H21F3LiN2O5+ (MH+) 541.1557, found 541.1539.

4.12: 1H NMR (500 MHz, DMSO) δ 11.82 (s, 1H), 9.70 (s, 1H),
8.56 (d, J = 8.3 Hz, 1H), 7.85 (dd, J = 7.7, 1.7 Hz, 1H), 7.74 (m,
3H), 7.48 (dd, J = 8.1, 1.5 Hz, 1H), 7.44 (s, 1H), 7.36 (dd, J = 7.5,
1.1 Hz, 1H), 7.33 (m, 2H), 7.27 (td, J = 7.8, 1.5 Hz, 1H), 7.15
(ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.11 (dd, J = 8.1, 1.6 Hz, 1H), 7.09
(d, J = 5.7 Hz, 1H), 5.95 (d, J = 5.7 Hz, 1H), 2.77 (m, 1H), 2.59 (m, 2H), 2.27 (m, 1H).
13

C NMR (126 MHz, DMSO) δ 195.2, 173.0, 172.8, 139.8, 138.5, 137.6, 136.1, 135.8,

135.0, 134.1, 132.2, 131.4, 130.9, 128.4, 128.1, 127.8, 127.5, 125.9, 124.4, 123.6, 120.3,
104.1, 95.1, 91.8, 30.4, 28.3. HRMS (ESI) calcd for C29H21F3LiN2O5+ (MH+) 541.1557,
found 541.1578.

Irradiation of N-(2-(((2-acetylphenyl)carbamoyl)carbonyl)phenyl)-3-(furan-2yl)propanamide (4.7b): General procedure C was followed using 0.35 g of 4.7b (0.87
mmol) in DCM (250 mL). Following the irradiation, the solution was concentrated to 40
mL, the mixture was centrifuged, the precipitate formed was filtered, washed with cold
DCM (3 x 10 mL) followed by water (3 x 10 mL), and dried in a desiccator yielding pure
4,23-dihydroxy-23-methyl -2-oxa-7,16109

diazaheptacyclo[11.9.2.03,7.03,25.08,13.016,24.017,22]pentacos-17(18),19(20),21(22)hexaene-6,15-dione (4.10) (0.12 g, 34%). The filtrate was purified by flash
chromatography (DCM/MeOH) yielding pure 5-(2-acetylphenyl)-2-oxa,5,14-diazapentacyclo[10.5.1.01,14.04,8.08,13]octadec-8(9),10(11),12(13)-triene-6,15-dione (4.11b)
(0.049 g, 14%) and N‐(2‐acetylphenyl)‐12‐hydroxy‐4‐oxo‐16‐oxa‐5‐azatetracyclo[11.2.1.0¹,⁵.0⁶,¹¹]hexadeca‐6,8,10,14‐tetraene‐12‐carboxamide (4.9b) (0.084
g, 24%).

4.10b: 1H NMR (500 MHz, DMSO) δ 8.29 (dd, J = 8.4, 1.3 Hz,
1H), 8.12 (dd, J = 8.0, 1.6 Hz, 1H), 7.78 (dd, J = 8.0, 1.3 Hz,
1H), 7.53 (dd, J = 7.8, 1.5 Hz, 1H), 7.31 (m, 2H), 7.22 (td, J =
7.5, 1.3 Hz, 1H), 7.14 (td, J = 7.7, 1.3 Hz, 1H), 6.63 (s, 1H), 4.78
(dd, J = 7.6, 4.5 Hz, 1H), 4.54 (s, 1H), 4.10 (d, J = 4.6 Hz, 1H),
3.26 (d, J = 7.5 Hz, 1H), 2.77 (dt, J = 16.8, 9.4 Hz, 1H), 2.65 (dd, J = 13.1, 8.4 Hz, 1H),
2.20 (m, 1H), 1.49 (s, 3H).

13

C NMR (126 MHz, DMSO) δ 174.6, 171.6, 135.8, 134.9,

133.3, 129.9, 128.8, 128.1, 126.7, 126.7, 126.0, 124.0, 122.1, 119.0, 98.5, 78.6, 71.9,
68.2, 60.3, 51.3, 32.1, 30.6, 30.4. HRMS (ESI) calcd for C23H20LiN2O5+ (MLi+)
411.1527, found 411.1547.
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4.11b: 1H NMR (500 MHz, CDCl3) δ 8.30 (dd, J = 8.3, 1.2 Hz,
1H), 8.05 (dd, J = 8.0, 1.5 Hz, 1H), 7.81 (dd, J = 7.7, 1.6 Hz, 1H),
7.57 (td, J = 7.7, 1.6 Hz, 1H), 7.50 (td, J = 7.6, 1.3 Hz, 1H), 7.45
(ddd, J = 8.6, 7.5, 1.6 Hz, 1H), 7.22 (td, J = 7.7, 1.3 Hz, 1H), 7.13
(dd, J = 7.8, 1.3 Hz, 1H), 4.84 (dt, J = 9.1, 5.3 Hz, 1H), 3.91 (m,
2H), 3.69 (d, J = 9.2 Hz, 1H), 3.49 (s, 1H), 2.81 (dt, J = 17.1, 9.4 Hz, 1H), 2.62 (s, 3H),
2.44 (m, 2H), 2.32 (dt, J = 13.2, 9.7 Hz, 1H).

13

C NMR (126 MHz, CDCl3) δ 199.7,

174.0, 173.1, 136.8, 135.0, 133.7, 132.7, 130.0, 129.6, 128.7, 128.2, 127.3, 126.7, 125.5,
121.7, 98.3, 71.6, 69.7, 63.3, 54.9, 31.6, 29.8, 28.7. HRMS (ESI) calcd for
C23H20LiN2O5+ (MLi+) 411.1527, found 411.1530.

4.9b: 1H NMR (500 MHz, CDCl3) δ 12.97 (s, 1H), 8.96 (dd, J =
8.4, 1.2 Hz, 1H), 8.00 (dd, J = 8.0, 1.6 Hz, 1H), 7.66 (m, 1H),
7.47 (dd, J = 8.1, 1.3 Hz, 1H), 7.35 (ddd, J = 8.7, 6.9, 2.0 Hz,
1H), 7.26 (ddd, J = 8.4, 7.4, 1.2 Hz, 1H), 7.20 (dd, J = 8.0, 1.9
Hz, 1H), 7.17 (ddd, J = 8.0, 6.9, 1.4 Hz, 1H), 6.75 (dd, J = 5.8,
2.0 Hz, 1H), 5.70 (dd, J = 5.8, 1.1 Hz, 1H), 4.89 (dd, J = 2.0, 1.2 Hz, 1H), 4.67 (s, 1H),
2.82 (dt, J = 17.1, 9.7 Hz, 1H), 2.71 (s, 3H), 2.64 (ddd, J = 17.4, 9.6, 1.7 Hz, 1H), 2.54
(dt, J = 13.8, 9.8 Hz, 1H), 2.46 (ddd, J = 13.6, 9.1, 1.4 Hz, 1H).

13

C NMR (126 MHz,

CDCl3) δ 201.8, 173.2, 171.1, 139.4, 137.1, 134.8, 134.0, 133.2, 131.7, 129.4, 128.6,
128.4, 127.9, 127.8, 126.7, 123.4, 120.9, 104.1, 85.4, 85.1, 30.1, 28.8, 28.6. C23H21N2O5+
(MH+) 405.1445, found 405.1461.
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Irradiation of N-(2-(((2-acetyl-4-bromophenyl)carbamoyl)carbonyl)phenyl)-3-(furan-2yl)propanamide (4.7c): General procedure C was followed using 0.25 g of 4.7c (0.52
mmol) in DCM (250 mL). The mixture was purified by flash chromatography yielding
pure 20-bromo-14,23-dihydroxy-23-methyl -2-oxa-7,16diazaheptacyclo[11.9.2.03,7.03,25.08,13.016,24.017,22]pentacos-17(18),19(20),21(22)hexaene-6,15-dione (4.10c) (0.055 g, 21%), 5-(2-acetyl-4-bromophenyl)-2-oxa,5,14diaza-pentacyclo[10.5.1.01,14.04,8.08,13]octadec-8(9),10(11),12(13)-triene-6,15-dione
(4.11c) (0.033 g, 13%), and N‐(2‐acetyl-4-bromophenyl)‐12‐hydroxy‐4‐oxo‐16‐oxa‐5‐
aza-tetracyclo[11.2.1.0¹,⁵.0⁶,¹¹]hexadeca‐6,8,10,14‐tetraene‐12‐carboxamide (4.9c)
(0.035 g, 14%).

4.10c: 1H NMR (500 MHz, DMSO) δ 8.31 (dd, J = 8.4, 1.2 Hz,
1H), 8.08 (dd, J = 8.0, 1.6 Hz, 1H), 7.83 (d, J = 8.7 Hz, 1H),
7.65 (d, J = 2.4 Hz, 1H), 7.49 (dd, J = 8.7, 2.4 Hz, 1H), 7.30
(ddd, J = 8.4, 7.3, 1.7 Hz, 1H), 7.15 (ddd, J = 7.9, 7.2, 1.3 Hz,
1H), 6.69 (s, 1H), 5.01 (s, 1H), 4.82 (dd, J = 7.3, 4.0 Hz, 1H),
4.09 (d, J = 4.0 Hz, 1H), 3.26 (d, J = 6.9 Hz, 1H), 2.73 (m, 2H), 2.45 (m, 1H), 2.17 (ddd,
J = 13.0, 10.5, 9.0 Hz, 1H), 1.49 (s, 3H).

13

C NMR (126 MHz, DMSO) δ 174.8, 171.8,

138.1, 133.7, 133.3, 130.8, 130.0, 129.6, 128.9, 126.1, 124.0, 123.4, 118.7, 118.1, 98.0,
77.4, 72.0, 68.1, 60.2, 50.9, 32.1, 31.6, 30.4. HRMS (ESI) calcd for C23H19BrLiN2O5+
(MLi+) 489.0632, found 489.0619.
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4.11c: 1H NMR (500 MHz, CDCl3) δ 8.31 (dd, J = 8.2, 1.3 Hz,
1H), 8.00 (dd, J = 8.0, 1.5 Hz, 1H), 7.88 (d, J = 2.3 Hz, 1H), 7.69
(dd, J = 8.4, 2.2 Hz, 1H), 7.46 (ddd, J = 8.2, 7.4, 1.5 Hz, 1H), 7.22
(td, J = 7.7, 1.3 Hz, 1H), 7.02 (d, J = 8.4 Hz, 1H), 4.82 (ddd, J =
9.2, 6.1, 4.6 Hz, 1H), 3.92 (dd, J = 10.0, 6.1 Hz, 1H), 3.87 (dd, J =
10.1, 4.6 Hz, 1H), 3.66 (d, J = 9.1 Hz, 1H), 3.22 (s, 1H), 2.83 (dt, J = 17.2, 9.5 Hz, 1H),
2.60 (s, 3H), 2.52 (ddd, J = 17.2, 9.5, 2.2 Hz, 1H), 2.45 (ddd, J = 13.2, 9.2, 2.2 Hz, 1H),
2.33 (dt, J = 13.2, 9.7 Hz, 1H).

13

C NMR (126 MHz, DMSO) δ 198.2, 173.5, 173.0,

139.6, 135.0, 133.8, 133.7, 131.3, 129.2, 128.8, 128.2, 127.8, 124.5, 120.5, 120.4, 98.4,
71.5, 68.0, 61.8, 53.7, 31.2, 29.9, 28.7. HRMS (ESI) calcd for C23H19BrLiN2O5+ (MLi+)
489.0632, found 489.0617.

4.9c: 1H NMR (500 MHz, CDCl3) δ 12.88 (s, 1H), 8.90 (d, J =
9.0 Hz, 1H), 8.08 (d, J = 2.4 Hz, 1H), 7.74 (dd, J = 9.0, 2.4 Hz,
1H), 7.47 (dd, J = 8.0, 1.2 Hz, 1H), 7.35 (ddd, J = 8.1, 6.8, 2.0
Hz, 1H), 7.16 (m, 2H), 6.72 (dd, J = 5.8, 2.0 Hz, 1H), 5.70 (dd, J
= 5.8, 1.1 Hz, 1H), 4.97 (s, 1H), 4.87 (dd, J = 1.9, 1.1 Hz, 1H),
2.74 (dd, J = 17.4, 9.8 Hz, 1H), 2.70 (s, 3H), 2.58 (m, 1H), 2.52 (dt, J = 13.8, 9.7 Hz, 1H)
2.44 (ddd, J = 13.7, 9.3, 1.5 Hz, 1H).

13

C NMR (126 MHz, CDCl3) δ 200.6, 173.4, 171.3,

138.3, 137.4, 136.9, 134.2, 133.8, 133.2, 129.3, 128.6, 128.5, 127.9, 126.7, 124.8, 122.6,
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115.8, 104.1, 85.5, 85.1, 30.0, 28.8, 28.6. HRMS (ESI) calcd for C23H19BrLiN2O5+
(MLi+) 489.0632, found 489.0615.

Irradiation of 3-(furan-2-yl)-N-(2-(((8-oxo-5,6,7,8-tetrahydronaphthalen-1yl)carbamoyl)carbonyl)phenyl)propanamide (4.7d): General procedure C was followed
using 0.45 g of 4.7d (1.0 mmol) in DCM (200 mL). Following the irradiation, the
solution was concentrated to 25 mL, the mixture was centrifuged, the precipitate formed
was filtered, washed with cold DCM (3 x 10 mL) followed by water (3 x 10 mL), and
dried in a desiccator yielding pure 14,25-Dihydroxy-2-oxa-7,16diazaoctacyclo[12.11.2.117,21.03,7.03,27.08,13.016,26.025,28]octacos8(9),10(11),12(13),17(18),19(20),21(28)-hexaene-6,15-dione (4.10d) (0.15 g, 35%). The
filtrate was purified by flash chromatography (DCM/MeOH) yielding pure 5-(8-Oxo5,6,7,8-tetrahydronaphthalen-1-yl)-2-oxa,5,14-diazapentacyclo[10.5.1.01,14.04,8.08,13]octadec-8(9),10(11),12(13)-triene-6,15-dione (4.11d)
(0.10 g, 23%) and 12-Hydroxy-4-oxo-N-(8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)16-oxa-5-azatetracyclo[11.2.1.0¹,⁵.0⁶,¹¹]hexadeca-6,8,10,14-tetraene-12-carboxamide
(4.9d) (0.052 g, 12%).
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4.10d: 1H NMR (500 MHz, DMSO) δ 8.22 (dd, J = 8.0, 1.6 Hz,
1H), 8.20 (dd, J = 8.3, 1.3 Hz, 1H), 7.33 (ddd, J = 8.6, 7.4, 1.5
Hz, 1H), 7.28 (m, 2H), 7.12 (ddd, J = 8.2, 7.3, 1.3 Hz, 1H), 7.03
(dd, J = 7.1, 1.8 Hz, 1H), 6.50 (s, 1H), 4.62 (dd, J = 9.0, 6.7 Hz,
1H), 4.13 (d, J = 6.7 Hz, 1H), 3.32 (d, J = 8.9 Hz, 1H), 3.25 (s,
1H), 2.77 (dt, J = 17.0, 9.5 Hz, 1H), 2.67 (s, 2H), 2.55 (m, 1H), 2.46 (m, 1H), 2.33 (dt, J
= 13.2, 9.7 Hz, 1H), 1.94 (m, 1H), 1.66 (m, 3H). 13C NMR (126 MHz, DMSO) δ 173.6,
171.2, 139.2, 137.0, 133.3, 131.7, 129.4, 128.8, 128.2, 128.2, 127.2, 124.5, 122.1, 120.1,
100.6, 81.7, 71.5, 66.6, 60.7, 52.4, 37.7, 32.0, 30.0, 29.2, 18.8. HRMS (ESI) calcd for
C25H22LiN2O5+ (MLi+) 437.1683, found 437.1710.

4.11d: 1H NMR (500 MHz, CDCl3) δ 8.33 (dd, J = 8.3, 1.2 Hz,
1H), 8.14 (dd, J = 8.0, 1.6 Hz, 1H), 7.51 (t, J = 7.8 Hz, 1H), 7.44
(ddd, J = 8.4, 7.4, 1.5 Hz, 1H), 7.38 (dd, J = 7.8, 1.2 Hz, 1H),
7.22 (td, J = 7.7, 1.3 Hz, 1H), 6.97 (d, J = 7.7 Hz, 1H), 4.69 (m,
1H), 3.86 (dd, J = 10.1, 4.0 Hz, 1H), 3.82 (dd, J = 10.1, 6.0 Hz,
1H), 3.75 (d, J = 9.2 Hz, 1H), 3.48 (d, J = 2.3 Hz, 1H), 3.06 (m, 2H), 2.82 (dt, J = 17.2,
9.5 Hz, 1H), 2.76 (m, 1H), 2.67 (ddd, J = 16.9, 7.8, 4.9 Hz, 1H), 2.52 (ddd, J = 17.2, 9.5,
2.1 Hz, 1H), 2.43 (ddd, J = 13.2, 9.2, 2.2 Hz, 1H), 2.31 (dt, J = 13.2, 9.7 Hz, 1H), 2.17
(m, 2H).

13

C NMR (126 MHz, CDCl3) δ 198.0, 174.4, 173.2, 147.6, 137.0, 133.8, 133.6,

130.4, 129.8, 128.5, 128.5, 127.4, 127.1, 125.4, 121.3, 98.4, 71.4, 69.2, 63.0, 54.9, 40.4,
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31.2, 30.5, 29.8, 22.7. HRMS (ESI) calcd for C25H22LiN2O5+ (MLi+) 437.1683, found
437.1695.

4.9d: 1H NMR (500 MHz, CDCl3) δ 13.40 (s, 1H), 8.83 (dd, J =
8.4, 1.1 Hz, 1H), 7.54 (t, J = 8.0 Hz, 1H), 7.46 (dd, J = 8.0, 1.3
Hz, 1H), 7.34 (ddd, J = 8.0, 7.0, 1.8 Hz, 1H), 7.20 (dd, J = 8.0,
1.7 Hz, 1H), 7.16 (ddd, J = 8.1, 7.0, 1.4 Hz, 1H), 7.07 (dd, J =
7.6, 1.0 Hz, 1H), 6.75 (dd, J = 5.8, 2.0 Hz, 1H), 5.70 (dd, J = 5.8,
1.1 Hz, 1H), 4.89 (dd, J = 2.0, 1.1 Hz, 1H), 4.75 (s, 1H), 3.04 (t, J = 6.1 Hz, 2H), 2.80
(dt, J = 17.2, 9.7 Hz, 1H), 2.74 (dd, J = 7.4, 5.7 Hz, 2H), 2.62 (ddd, J = 17.1, 9.6, 1.6 Hz,
1H), 2.53 (dt, J = 13.9, 9.8 Hz, 1H), 2.45 (ddd, J = 13.8, 9.3, 1.6 Hz, 1H), 2.13 (p, J = 6.5
Hz, 2H).

13

C NMR (126 MHz, CDCl3) δ 202.3, 173.2, 171.2, 146.2, 140.4, 137.2, 134.7,

134.1, 133.2, 129.5, 128.5, 128.3, 127.8, 126.7, 124.1, 119.7, 118.4, 104.1, 85.5, 85.2,
40.7, 31.0, 30.1, 28.8, 22.7. HRMS (ESI) calcd for C25H22LiN2O5+ (MLi+) 437.1683,
found 437.1670.

One pot procedure for the synthesis of 14,23-dihydroxy-23-methyl -2-oxa-7,16diazaheptacyclo[11.9.2.03,7.03,25.08,13.016,24.017,22]pentacos-17(18),19(20),21(22)hexaene-6,15-dione (4.10b):

Isatin (0.20 g, 1.4 mmol) was added to 3-(2-furyl)propionic acid (0.23 g, 1.6
mmol) solution in DCM (10 mL) at 0 °C, followed by EDC (0.31 g, 1.6 mmol) and
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DMAP (0.017 g, 0.14 mmol). The reaction mixture was allowed to stir at room
temperature for three hours. The mixture was then treated with 2′-aminoacetophenone
(0.22 g, 1.6 mmol) and stirred overnight. After that, the mixture was diluted with DCM
(50 mL) and washed with 5% aq. HCl, water, a solution of sat. aq. NaHCO3, and water
(25 mL each). The organic layer was dried over Na2SO4, filtered, and concentrated. The
crude product was then dissolved in DCM (250 mL), degassed with N2 and irradiated in
Pyrex or borosilicate glass reaction vessels in a Rayonet reactor equipped with RPR-3500
UV lamps (broadband 300-400 nm UV source with peak emission at 350 nm) until
consumption of the starting material and [4 + 2] cycloaddition products was observed, as
determined by 1H NMR. Following the irradiation, the solution was concentrated to 25
mL, the mixture was centrifuged, the precipitate formed was filtered, washed with cold
DCM (3 x 10 mL), followed by water (3 x 10 mL), and dried in a desiccator yielding pure
4.10d (0.22, 39% over two steps).
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Chapter 5: Conclusion
The synthetic utility of o-azaxylylene cycloadditions in the excited state has
grown rapidly since this methodology was introduced in 2011,20 and will likely continue
to grow at an even greater rate. The excited state reaction pathway is no longer a black
box, and has been shown to proceed through excitation to the singlet state, where ESIPT
takes place, followed by intersystem crossing, an N-centered radical attack on the
dienophile, and radical recombination yielding the [4 + 4] and [4 + 2] cycloaddition
products. This information will prove to be invaluable to those who utilize this
methodology in the future.
From this work it is clear that these cycloadditions follow the philosophy of
diversity oriented synthesis, as they are capable of producing complex, and diverse
scaffolds with good diastereoselectivity, and can probe an even greater region of
chemical space, as these cycloaddition products are amenable to post-photochemical
modifications such as palladium catalyzed cross coupling reactions.
Cascade reactions involving o-azaxylylenes cores have been shown to yield fused
sp3 cyclic systems containing multiple fused rings, chiral centers, hydrogen bond donors
and acceptors, as well as few rotatable bonds keeping in keeping with the general
characteristics of approved drug sources.6 These complex structures can be synthesized
efficiently, as the photoprecursors can be obtained in a one-pot two-step reaction from
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commercially available starting materials, and the [4 + 2]/[4 + 2] cascade products
precipitate out of solution upon irradiation requiring no chromatographic purification.
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Appendix B: List of Abbreviations
Δ

temperature (heat)

Φ

quantum yield

Ac

acetyl

ACN

acetonitrile

aq.

aqueous

Ar

aryl

ca.

circa

calcd

calculated

cat.

catalyst (or catalytic amount)

DCM

dichloromethane

DFT

density functional theory

DBU

1,8-diazabicyclo[5.4.0]undec-7-ene

DIBAl-H

diisobutylaluminum hydride

DIPEA

N,N-diisopropylethylamine

DMAP

4-(dimethylamino)pyridine

DME

dimethoxyethane

DMF

dimethylformamide

DMSO

dimethyl sulfoxide

DOS

diversity oriented synthesis

EDC

N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride

ESIPT

excited state intramolecular proton transfer
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Et

ethyl

eq

equivalent

FVT

flash vacuum thermolysis

h

hour(s)

hex

hexane

HOMO

highest occupied molecular orbital

HPLC

high-performance liquid chromatography

HRMS

high-resolution mass spectrum

hν

light (irradiation)

IPT

intramolecular proton transfer

ISC

intersystem crossing

Kdiff

rate of diffusion

Ksv

Stern-Volymer constant

LED

light emitting diode

LUMO

lowest unoccupied molecular orbital

LC

liquid chromatography

Me

methyl

MIDA

N-methyliminodiacetic acid

min

minute(s)

MS

mass spectroscopy

NMR

nuclear magnetic resonance

NPMI

N-phenylmaleimide
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P

product

PCC

pyridinium chlorochromate

PCy3

tricyclohexylphosphine

Ph

phenyl

i-Pr

iso-propyl

Py

pyridine

R

reactant

RA

radical addition

r.t.

room temperature

S

goodness of fit

S1

first singlet excited state

sat.

saturated

SOC

spin orbit coupling

TCSPC

time correlated single photon counting

TEA

triethylamine

THF

tetrahydrofuran

TMS

trimethylsilane

TOS

target oriented synthesis

UV

ultraviolet
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